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ABSTRACT 
 
DIRECT INCREMENTAL COSTS IN CHRONIC OBSTRUCTIVE PULMONARY 
DISEASE (COPD) AND ASTHMA IN UNITED STATES – AN ANALYSIS OF 2007 
MEDICAL EXPENDITURE PANEL SURVEY DATA 
 
 
 
By 
Bhavini Patel Srivastava 
October 12
th
 2011 
 
Thesis Supervised by Dr. Khalid M. Kamal 
Objective: To estimate  national prevalence and  direct incremental expenditures in 
Chronic Obstructive Pulmonary Disease (COPD) and asthma using  2007 Medical 
Expenditure Panel Survey (MEPS) data. 
Methods: COPD and asthma were identified using ICD-9 codes and were the main 
independent variables. Covariates included age, gender, race, income, region, insurance 
and marital status. Dependent variables were total health care, office-based, outpatient, 
inpatient, emergency room and prescription expenditures.  Descriptive statistics and 
regression analysis were used to fulfill the study objectives. 
 v 
 
 
Results: Prevalence of COPD and asthma was 1.3 million and 28.3 million, respectively. 
Total direct incremental health care expenditures per person for COPD and asthma were 
$1,739.27 and $2,133.83, respectively. High cost categories among COPD and asthma 
included office-based, inpatient and prescription expenditures. Age, gender, region, 
insurance and marital status were significant predictors for health care expenditures. 
Conclusion: Results highlight socio-demographic disparities and high health care 
expenditures due to COPD and asthma in the United States. 
Keywords:  Asthma, COPD, Medical Expenditures Panel Survey (MEPS), incremental 
health care expenditures, retrospective analysis 
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CHAPTER ONE 
INTRODUCTION 
 
Patients with Chronic Obstructive Pulmonary Disease (COPD) and asthma 
display similar symptoms which include coughing, wheezing, and shortness of breath 
since lung inflammation is common in both conditions.
1,2  
However, both conditions 
differ in terms of disease onset, frequency of symptoms and reversibility of airflow 
obstruction.
1,2 
 
The  Global Initiative for Chronic Obstructive Lund Disease (GOLD) guidelines 
define COPD as a preventable and treatable disease with some significant extra-
pulmonary effects that may contribute to the disease severity.
1  
The pulmonary 
component is characterized by airflow limitation that is not fully reversible.  Airflow 
limitation is usually progressive and associated with an abnormal inflammatory response 
of the lungs to noxious particles or gases.  
 
 
Expert Panel Report-3 (EPR-3) defines asthma as a common chronic disorder of 
the airways that is complex and characterized by variable and recurring symptoms, 
airflow obstruction, bronchial hyper-responsiveness, and an underlying inflammation.
3 
 
The interaction of these features of asthma determine the manifestations, severity of the 
disease and response to treatment.  
 2 
 
 
Pathophysiology  
 
In COPD, cigarette smoke and chronic irritants such as noxious particles, biomass 
particles cause inflammation in the lungs which is further amplified due to oxidative 
stress and an excess of proteinases in the lungs.
1  
Due to repeated injury and repair, 
inflammatory cells such as neutrophils, macrophages, and lymphocytes increase in the 
proximal airways, peripheral airways, lung parenchyma and pulmonary vasculature 
which further leads to chronic inflammation.
1
  As a result of this underlying disease 
process, characteristic physiological abnormalities such as airflow limitation and air 
trapping, gas exchange abnormalities and pulmonary hypertension occurs.
 1
 The airflow 
limitation in COPD occurs due to broncho-constriction and airway re-modeling which 
involves permanent structural changes in the airways.
1
  Thus, the structural damage 
caused is irreversible. 
 
The genetic predisposition for the development of an immunoglobulin E (IgE)-
mediated response to common aeroallergens ( Atopy)  is the strongest identifiable 
predisposing factor for developing asthma.  Pathophysiology of asthma involves airway 
inflammation, intermittent airflow obstruction and bronchial hyper-responsiveness.  Mast 
cells, eosinophils, T-lymphocytes, macrophages, neutrophils and epithelial cells play a 
role in the inflammation of the airways.
3
  This inflammation causes recurrent episodes of 
wheezing, breathlessness, chest tightness and coughing, particularly at night or early in 
the morning.
3  
 Unlike COPD, episodes in asthma are associated with variable airflow 
obstruction that may only be partially reversible either spontaneously or with treatment.
3
  
 3 
 
 
Epidemiology 
 
The morbidity and mortality due to COPD is substantial in the United States (US). 
However, prevalence estimates may have been underestimated due to misdiagnosis of 
cases.
4
  Approximately, 16 million people had COPD in the US in 2004.
5
  An additional 
of 24 million people during 2004 presented with symptoms of impaired lung function. 
This may suggest a misdiagnosis of COPD.
6
  The condition has been more prevalent 
among men than women.
7
  Furthermore the disease is common in countries where 
smoking rates are relatively high.
8
  Since smoking is the most significant risk factor for 
COPD. Mortality in COPD has been high and continues to rise and is currently the fourth 
leading cause of death in the US and is projected to be the third most common cause of 
death by the year 2020.
5
  Disparities in mortality rates have also been observed based on 
gender. From 1980 to 2000, the death rate from COPD grew much faster in women than 
men.
9
  Also, death rate rose from 20.1 to 56.7 deaths per 100,000 women compared to 
73.0 to 82.6 deaths per 100,000 men.
9
   
 
According to Centre for Disease Control and Prevention (CDC) estimates, 
prevalence of asthma in 2005 was approximately 22.2 million in the US.
11
  From 1980 to 
1994, the asthma prevalence increased by 75%.
10
   Furthermore, World Health 
Organizations (WHO) estimates that the number of people with asthma will grow by 
more than 100 million by 2025.
12 
 Studies using National Surveillance data have shown 
that asthma is more prevalent in women and among people of African American 
ethnicity.
13
  In 2006, the prevalence of asthma in adult females was 23% higher than  
 4 
 
 
males and 20.1% higher in African Americans than in whites.
14
  Furthermore, in 2007, 
over 12 million people in the US reported an asthma attack.
15   
Mortality in asthma is 
considerably high. According to the American Lung Association (ALA), asthma was 
responsible for 3,384 deaths in the 2005.
14 
 Moreover, the death rates have increased 
more than 50% among all genders, age groups and ethnic groups since 1980.
16
  Mortality 
is higher in females than males, with women accounting for nearly 65% of asthma 
deaths.
16
  Mortality due to asthma is also three times higher in African Americans.
16
  
Furthermore, mortality rate in African American women is 2.5 times higher than 
Caucasian women.
16
  The reason for this disparity could be the higher prevalence of 
asthma among African Americans.  
 
Risk Factors 
 
Risk factors associated with COPD include cigarette smoking, exposure to 
occupational dust/vapors, and indoor and outdoor air pollutants. About 80-90% of 
patients diagnosed with COPD have a history of smoking and the risk of COPD also 
increases with exposure to passive smoking.
17
  Other risk factors include genetic risk 
factors, low birth weight, and a history of severe childhood respiratory infections.
1
  One 
of the genetic risk factor for COPD that is well documented is the deficiency of 
antitrypsin which  occurs in 1-2% of patients with COPD.
18 
 
Host factors that influence development of asthma include genetics, obesity and 
gender.
3,19 
 Individuals who develop asthma due to genetics, have genes predisposing to 
 5 
 
 
atopy and airway hyper-responsiveness.
3
  In addition, exposure to indoor allergens (dust 
mites, furred animals and cockroach allergens), outdoor allergens (pollen, fungi, molds, 
yeast), infections (predominantly viral), indoor and outdoor pollution and tobacco smoke 
contribute to the development of asthma.
3
  Tobacco smoke causes functional decline of 
the lungs in people with asthma. Moreover, patients who smoke become less responsive 
to treatment with inhaled and systemic gluco-corticosteroids which makes it difficult to 
manage the disease.
3 
 
Socioeconomic Burden 
 
The costs of COPD and asthma are substantial in the US health care system. 
Direct medical costs (e.g., hospital admissions, cost of medications) as well as indirect 
medical costs (e.g., missed work days, premature death) contribute to the economic 
burden of COPD and asthma.
 
According to the National Heart, Lung and Blood Institute 
(NHLBI), the total annual cost of treating COPD in the US is $38.8 billion.
20 
 Direct 
annual costs in the US in 2002 were $18 billion.
5
  Indirect morbidity costs and indirect 
mortality costs associated with COPD were $8.0 billion and $12.4 billion, respectively in 
2010.
21  
 Furthermore, COPD is also associated with disability due to impaired breathing. 
Social burden in terms of Disability-Adjusted Life Years (DALYs) in COPD is expected 
to double from a value of 2.1% of total DALYs in 1990 to 4.1% of total DALYs in 
2020.
22 
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The NHLBI estimates the annual expenditures for health and lost productivity due 
to asthma at $20 billion.
20
  Asthma accounts for nearly $10 billion of direct costs 
(hospitalizations were single largest portion of direct cost) and $8 billion of indirect costs 
(lost earnings due to illness or death).
21
  Furthermore, asthma accounts for 10.1 million 
missed work days for adults in the US.
16
  Additionally, in 2007,  prescription drugs 
contributed over $6 billion to direct medical expenditure related to asthma.
14 
 
In addition to the substantial economic impact, individuals with COPD 
demonstrate high symptom burden, high functional impairment and moderate impairment 
in quality of life (QoL).
22
  Studies have shown a correlation between symptom distress 
and impaired QoL among individuals with COPD.
22
  Similarly, individuals with asthma 
experience an impaired QoL due to troublesome symptoms such as coughing, wheezing, 
shortness of breath and chest tightness.
23
  These symptoms affect an individuals’ ability 
to carry out daily activities such as sports, climbing stairs, etc.
23
  Also, it has been noticed 
that women experience a greater impairment in QoL than men with asthma.
23
 
 
Disease Management  
 
Managing either COPD or asthma involves assessing and monitoring the disease, 
avoiding risk factors and use of pharmacotherapy based on disease symptoms. Treatment 
strategies depend on disease severity in both conditions. Diagnosis, disease severity, risk 
factors and pharmacotherapy for COPD and asthma is described in detail in the next 
section. 
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Diagnosis and Disease Severity in COPD 
A patient should be considered for clinical diagnosis of COPD if he or she 
displays symptoms of dyspnea, chronic cough, sputum production and/or a history of 
exposure to risk factors of the disease. The GOLD guidelines recommend spirometry to 
confirm the presence of COPD. Spirometry is considered the gold standard since it is a 
reproducible, standardized and objective method for measuring airflow limitation.
1 
  
Spirometry measures the forced expiratory volume in 1 second (FEV1).  It is very 
important to distinguish between COPD and asthma when diagnosing a patient since 
treatment strategies for both conditions are different.  In a study conducted by Tinkelman 
and colleagues (2006), more than half of the patients with COPD were misdiagnosed with 
asthma.
 4 
 
The GOLD guideline divides COPD into four disease severity levels. Table 1 displays 
COPD severity levels based on the FEV1 value. 
Stage I: Mild COPD is characterized by mild airflow limitation. Patients in this stage may 
display symptoms of chronic cough and sputum production.  At this stage, an individual 
may not be aware that his or her lung function is abnormal. 
Stage II:  Moderate COPD is characterized by worsening airflow limitation and an 
individual will display shortness of breath during exertion. Cough and sputum production 
may also be present sometimes. At this stage, an individual usually seeks medical 
attention due to chronic respiratory symptoms or an exacerbation of the disease. 
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Stage III: Severe COPD is characterized by further worsening of airflow limitation. The 
patient experiences greater shortness of breath, reduced exercise capacity, fatigue and 
repeated exacerbations that have an impact on patient’s QoL. 
Stage IV: Very severe COPD is characterized by severe airflow limitation in addition to 
the presence of respiratory failure and clinical signs of right heart failure. At this stage, a 
patient’s Qol is significantly impaired and exacerbations may be life threatening.  
 9 
 
 
Table 1. Classification of COPD severity based on Forced Expiratory Volume in 1 
second (FEV1) value 
Stage Severity FEV1/FVC 
I Mild FEV1/FVC <0.70 
FEV1 ≥ 80% predicted 
II Moderate FEV1/FVC <0.70 
50% ≤ FEV1 < 80% predicted 
III Severe FEV1/FVC <0.70 
30% ≤ FEV1 < 50% predicted 
IV Very Severe FEV1/FVC <0.70 
FEV1 < 30% predicted 
1  
FEV1= Forced Expiratory Volume in 1 second 
FVC= Forced Vital Capacity 
 
 
 
 
                                                             
1 Adapted from the Global Initiative for chronic obstructive lung disease ( GOLD) 
guideline 2009. Available at www.goldcopd.com 
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Diagnosis and Disease Severity in Asthma 
According to the Expert Panel Recommendations, diagnosis of asthma should be 
considered if any of the following key indicators are present in an individual.
3
 
o Wheezing- high-pitched whistling sound when breathing out. 
o Any history of cough particularly worse at night, recurrent wheeze, recurrent 
difficulty in breathing, recurrent chest tightness. 
o Symptoms worsen in the presence of exercise, viral infection, animal dander, 
house dust mites, mold, smoke, pollen, changes in weather, strong emotional 
expression, airborne chemicals or dust. 
o Symptoms occur or worsen at night, awakening the patient. 
 
The methods recommended to establish the diagnosis are detailed medical history, 
physical exam on the upper respiratory tract, chest and skin and spirometry to 
demonstrate obstruction and assess reversibility. According to the Expert Panel 
recommendations, spirometry measurements of FEV1 in 6 seconds should be taken before 
and after the patient inhales a short-acting bronchodilator.
3
  This will determine the 
presence, severity, and reversibility of airflow obstruction. Asthma classification based 
on severity levels are described in Table 2. 
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Table 2. Classifying asthma severity in youths ≥12 years of age and adults 
 
Stage Spirometry Presence of Daytime 
Symptoms and 
Exacerbations 
Presence of Night-
time Symptoms 
Mild intermittent FEV1 or PEF ≥80% 
predicted  
PEF variability <20% 
Symptoms: ≤2 times 
per week2 
Exacerbations: brief 
and varying intensity 
Symptoms: ≤2 times 
per month 
Mild persistent FEV1 or PEF ≥80% 
predicted  
PEF variability 20%-
30% 
Symptoms: >2 times 
per week but <1 time 
per day 
Exacerbations: may 
affect activity 
Symptoms: >2 times 
per month 
Moderate 
persistent 
FEV1 or PEF 60%-80% 
predicted  
PEF variability >30% 
Symptoms: daily 
Exacerbations: affect 
activity, ≥2 times per 
week 
Symptoms: >1 time 
per week 
Severe persistent FEV1 or PEF ≤60% 
predicted  
PEF variability >30% 
Symptoms: continuous 
Exacerbations: limit 
activity frequent 
Symptoms: frequent 
FEV1= Forced Expiratory Volume in 1 Second 
PEF= Peak Expiratory Flow  
 
                                                             
2 Adapted from the National Heart, Lung and Blood Institute Expert Panel Report 3 
Guidelines for the Diagnosis and Management of Asthma  2007.  
Available at www.nhlbi.nih.gov 
 12 
 
 
Prevention of Risk Factors  
 
It is important to reduce exposure to risk factors such as cigarette smoking, 
occupational dust/vapor, indoor and outdoor allergens in order to manage COPD and 
asthma effectively. Prevention of risk factors will reduce further progression of COPD. 
For individuals with asthma, preventing risk factors will reduce asthma symtoms and 
asthma attacks.  Decreasing symptoms and preventing exacerbations in asthma and 
COPD may reduce associated costs.  A number of public health initiatives such as 
smoking cessation and also strategies aimed at reducing the burden of inhaled particles 
and gases at workplace are recommended in the management of COPD..The Expert Panel 
Recommendations for asthma suggests that clinicians should review a patient’s medical 
history to identify allergens that the patient is sensitive to
3  
 and educate the p to reduce 
their exposure to the identified allergens. Viral infections such as influenza commomly 
referred to as flu, can exacerbate asthma symptoms. The Expert Panel therefore, 
recommends individuals with asthma to get vaccinated against influenza every year. 
 
Pharmacologic Treatments for COPD 
 
Common classes of medications for treating COPD include the following: 
 Bronchodilators: These include short-acting and long-acting β2-agonists, 
methylxanthines, and anticholinergics. These drugs alter the airway smooth 
muscle tone and thus improve expiratory flow. Bronchodilators improve emptying 
of lungs, thus reducing dynamic hyperinflation at rest and during exercise. 
Bronchodilators play a central role in the management of COPD. These drugs are 
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given on an as-needed basis to relieve persistent or worsening symptoms, or on a 
regular basis to prevent or reduce symptoms. The choice of bronchodilators 
depends on the availability of the drug and patient’s response to the drug in terms 
of symptom relief and side effects experienced by the patient. The combination of 
bronchodilators of different pharmacological classes have been shown to improve 
efficacy and decrease the risk of side effects as compared to increasing the dose of 
a single bronchodilator. Using a long-acting beta agonist on a regular basis is 
more effective and convenient than using a short-acting beta agonist. Long-acting 
inhaled anti-cholinergic drugs have been shown to reduce the rate of 
exacerbations in COPD. 
 Inhaled glucocorticosteroids: Regular treatment with inhaled glucocorticosteroids 
have not been shown to modify the long term decline of FEV1 in patients with 
COPD.  However, regular treatment with inhaled glucocorticosteroids may reduce 
the frequency of exacerbations in COPD.  
 
Other pharmacological treatments used in COPD include vaccines, 
immunoregulators, antitussives, and vasodilators which help relieve symptoms and 
reduce severity of exacerbations. GOLD guidelines also recommended influenza vaccines 
in patients with COPD since it is known to decrease mortality rate. Among elderly 
patients with COPD, hospitalizations and death can be reduced by influenza vaccinations. 
Treatment guidelines according to disease severity in COPD are shown in Figure 1. 
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Figure 1. Treatment in COPD according to Disease Severity 
 
 
Adapted from the Global Initiative for chronic obstructive lung disease ( GOLD) 
guideline 2009. Available at www.goldcopd.com 
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Non-pharmacologic Treatment Options in COPD 
 
Non-pharmacological treatments used to manage COPD include the following: 
 Pulmonary rehabilitation:- Main objectives of this therapy are to reduce 
symptoms, improve QoL, and increase physical and emotional participation in 
everyday activities. This therapy covers a range of non-pulmonary problems that 
may not be adequately addressed by medical therapy for COPD.  
 Oxygen therapy:- It is the main non-pharmacologic treatment in patients with 
Stage IV (Very Severe) COPD. This treatment can be administered as long-term 
continuous therapy, during exercise, and to relieve acute dyspnea. Survival has 
been shown to increase in patients with chronic respiratory failure who went 
through oxygen therapy. 
 Ventilatory support:- Noninvasive ventilation is now widely used to treat acute 
exacerbations of COPD. 
 
Surgical Treatment Options in COPD 
Surgical treatment options in COPD include the following: 
 Bullectomy : This procedure involves the removal of a large bulla that does not 
contribute to gas exchange and decompresses the adjacent lung parenchyma. This 
procedure can be performed thoracoscopically. Bullectomy has been shown to 
reduce dyspnea and improvement in lung function among carefully selected 
patients with COPD. 
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 Lung Volume Reduction Surgery (LVRS): This procedure involves parts of the 
lungs to be resected to reduce hyperinflation which makes respiratory muscles 
more effective pressure generators by improving their mechanical efficiency. 
Expiratory flow rates are also improved since LVRS increases the elastic recoil 
pressure of the lung. 
 Lung Transplantation: This procedure has been shown to improve the QoL and 
functional capacity among appropriately selected patients with very advanced 
COPD. 
Managing Exacerbations in COPD 
 
An exacerbation in COPD is defined as an event in the natural course of the 
disease characterized by a change in the patient’s baseline dyspnea, cough, and/or sputum 
that is beyond normal day-to-day variations, is acute in onset, and may warrant a change 
in regular medication in a patient with underlying COPD. Exacerbations can be treated 
effectively using inhaled bronchodilators and oral glucocortisteroiods. Noninvasive 
mechanical ventilation has been shown to improve respiratory acidosis, decrease 
respiratory rate, severity of breathlessness, and decrease length of stay during 
exacerbations. 
 
Pharmacological Treatment in Asthma 
 
Treatments in asthma are divided into two general classes: 
 17 
 
 
1. Long-term control medications used to achieve and maintain control for persistent 
asthma. Long-term control medications include the following: 
 Corticosteroids reduce airway hyperresponsiveness, and inhibit 
inflammation. Inhaled corticosteroids (ICSs) are used in the long-term 
control of asthma and short courses of oral systemic corticosteroids are 
used to control the disease promptly when initiating long-term therapy. 
Long-term oral systemic corticosteroids are used for severe persistent 
asthma. 
 Cromolyn sodium and nedocromil is used as an alternative for treatment 
of mild persistent asthma. It can be used as preventive treatment prior to 
exercise or unavoidable exposure to known allergens. 
 Immunomodulators: Omalizumab, a monoclonal antibody, is used as an 
adjunctive therapy for patients  ≥12years of age who have allergies and 
severe persistent asthma. 
 Leukotriene modifiers: These include leukotriene receptor antagonists 
(LTRAs) (e.g., montekulast) and 5-lipooxygenase inhibitor (e.g., zileuton). 
LTRAs can be used as an alternative treatment. However, they are not 
preferred in the treatment of mild persistent asthma. LTRAs may also be 
used as an adjunct treatment along with ICSs.  
 Long-acting Beta Agonists (LABAs): Bronchodilators are used in 
combination with ICSs for long-term control and prevention of asthma 
symptoms in moderate or severe asthma. E.g., salmeterol.  
 18 
 
 
 Methylxanthine: A mild to moderate bronchodilator is used as an 
alternative but is not a preferred medication. 
2. Quick-relief medications used to treat acute symptoms and exacerbations. Quick-
relief medications include the following 
 Short-acting Beta Agonists (SABAs): Bronchodilators that relax smooth 
muscle e.g. albuterol. 
 Anticholinergics: Ipratropium bromide provides additive benefit to SABA 
in moderate to severe asthma exacerbations. It may be used as an 
alternative bronchodilator in patients who cannot tolerate SABA. 
 Systemic corticosteroids: These are used for moderate and severe 
exacerbations in combination with SABAs to speed recovery and prevent 
exacerbations. 
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Figure 2. Stepwise approach for managing asthma in adults. 
 
 
Adapted from the National Heart, Lung and Blood Institute Expert Panel Report 3 
Guidelines for the Diagnosis and Management of Asthma  2007. Available at 
www.nhlbi.nih.gov 
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PROBLEM STATEMENT 
 
The growing burden of COPD and asthma in terms of increasing prevalence and 
the use of health care resources imposes a tremendous burden on the US society. In 2000, 
COPD accounted for 1.5 million emergency room visits and 726,000 hospitalizations.
9
  
Individuals with COPD who are 50 years of age and older are considered disabled due to 
impaired breathing.
5
  This disability could be prevented with proper treatment strategies 
if the disease is detected in the earlier stages. Similar to COPD, asthma accounts for 2 
million emergency room visits annually accounting for a  quarter of all emergency room 
visits each year in the US.
16
  Furthermore, asthma is responsible for 500,000 
hospitalizations and 10 million outpatient visits each year.
16
  Individuals with asthma 
who have been hospitalized have an average length of stay of 3 days.
26
 
  
The use of medical therapies can help control symptoms in individuals with 
COPD or asthma. However, these treatments are costly and may not be affordable for 
everyone in the general population. Therefore, it becomes very important to compute the 
most recent cost estimate which will provide meaningful information in terms of 
prevalence and cost burden associated with these conditions. This will help decision 
makers in setting up priorities for resource allocation and evaluating possible treatment 
polices to manage these conditions and minimize the cost of treatment. Policy makers 
also need the most recent cost estimates for health care expenditures in COPD and 
asthma in order to implement cost-benefit studies and cost-effective analysis of 
pharmaceutical and medical interventions. 
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Even though the current literature reports a few cost estimates for COPD and 
asthma, we may not be able to generalize these cost estimates to the US population. Most 
of these cost estimates were calculated for specific population (e.g, state Medicaid 
group). Also, most of the previous studies have calculated these estimates from a single 
payer perspective. The most recent study that reports a nationally representative cost 
estimates in COPD from an all payer perspective was conducted by Miller et al. (2005) 
using the 2000 MEPS data.
27
  However, this cost estimate will need an update since the 
study analysis was conducted using data that was available seven years ago. Kamble and 
Bharmal (2009) report the most recent prevalence estimates for asthma and cost estimates 
in individuals with asthma using the 2004 MEPS data.
28
  The present study will further 
update the cost estimates reported by Kamble and Bharmal (2009) by using the 2007 
MEPS data.  
 
CONCEPTUAL FRAMEWORK 
 
The objective of this study is to determine a national estimate of the incremental 
expenditures associated with COPD and asthma. The study will provide incremental 
estimates for total expenditures, office-based expenditures, outpatient expenditures, 
inpatient expenditures, emergency room expenditures and prescription expenditures for 
both the conditions. The study will also describe the socio-demographic characteristics of 
individuals with COPD and individuals with asthma and will determine factors could 
predict the medical expenditures incurred by individuals with COPD or individuals with 
asthma. 
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To accomplish the objectives of this study, a retrospective database analysis was 
conducted using the 2007 Medical Expenditure Panel Survey (MEPS). The Agency for 
Health care Research and Quality (AHRQ) and National Center for Health Statistics 
(NCHS) co-sponsored MEPS to provide complete data on health care use, expenditures 
and insurance coverage. MEPS is a set of surveys that have been conducted annually 
since 1996 and provides a nationally representative sample of the ambulatory population 
in the US. MEPS is comprised of four components: Household Component, Medical 
Provider Component, Nursing Home Component and Insurance Component. 
 
Household Component (HC) collects data from a sample of families and 
individuals in selected communities across the US to provide data on demographic 
characteristics, health conditions, health insurance coverage, and medical expenditure.  
 
The HC is available from 1996-2007. It provides complete information on the 
demographic characteristics, health conditions, health status, expenditures, source of 
income, sources of payment, insurance coverage, and access to health care in individuals 
who were surveyed. It can be used to provide an estimate on expenditures from an all 
payer perspective. Furthermore, the estimates that are calculated from the data sample, 
can be projected to the national US population by using the person level weights provided 
by the database to extrapolate the results. The HC will be utilized to meet the objectives 
of this study. The 2007 full year consolidated data file and the 2007 medical conditions 
file will be utilized to fulfill the objectives of this study. 
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STUDY OBJECTIVES 
 
The aim of this study is to calculate the incremental cost burden that is associated 
with COPD and asthma compared to individuals without these conditions. The specific 
objectives are listed below. 
Objective 1: To determine the national prevalence of COPD and asthma in 2007. 
Objective 2: To describe the socioeconomic characteristics in individuals with COPD and 
asthma. 
Objective 3: To calculate mean total expenditures, mean office-based expenditures, mean 
outpatient expenditures, mean inpatient expenditures, mean emergency room 
expenditures and mean prescription expenditures in individuals with COPD and asthma. 
Objective 4: To determine the incremental expenditures for individuals with COPD and 
determine predictors for expenditures in individuals with COPD. 
Objective 5: To determine a national estimate for the incremental expenditure incurred by 
individuals with COPD in the US. 
Objective 6: To determine the incremental expenditures for individuals with asthma and 
determine predictors for expenditures in individuals with asthma. 
Objective 7: To determine a national estimate for the incremental expenditure incurred by 
individuals with asthma in the US. 
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SIGNIFICANCE OF THE STUDY 
 
This study will provide disparities in terms of prevalence and expenditures for 
COPD and asthma for 2007. The national estimates on expenditures provided in this 
study can serve as a guide for policy makers in the formulation of health care policies for 
COPD and asthma. These policies on screening, treatment guidelines, and identification 
of high risk population can help decision makers formulate effective intervention 
strategies. Early diagnosis of COPD or asthma can help us manage the disease better by 
starting the treatment earlier. This will prevent further progression of the disease which 
could improve QoL in these individuals. Early and appropriate treatment identification in 
these disease conditions will minimize health care resources by saving unnecessary 
emergency room visits and inpatient visits which will in turn help in cost savings among 
individuals with these disease conditions. Proper management strategies for COPD and 
asthma should be implemented in those individuals who already have either of these 
conditions. As mentioned earlier, proper management of these conditions can help 
improve the QoL in these individuals and minimize use of health care resources which 
will promote cost savings. 
 
This study will provide meaningful information for decision makers like private 
insurance companies and Medicare for setting priorities in resource allocation since it 
will highlight the magnitude of the economic impact of these diseases. Research funds 
would be better utilized by estimating the effectiveness, costs and benefits associated 
with disease prevention strategies. Since this study provides estimates on expenditures for 
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different service categories, a better picture will be provided in terms of which service 
category contributes most to the total expenditures in COPD and asthma. Strategies can 
be implemented to minimize expenditures in those high cost categories. 
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CHAPTER TWO 
LITERATURE REVIEW 
 
This chapter presents a detailed review of cost studies in COPD and asthma. A 
systematic literature search was conducted using Pubmed and Google Scholar. Articles 
that were published in the period of January 1999 to December 2010 were selected. The 
articles on direct health care expenditures associated with either COPD or asthma are 
reviewed in this chapter.  
 
Cost Studies in COPD 
Simoni-Wastila et al (2009) investigated the clinical and economic outcomes 
associated with COPD in Medicare beneficiaries residing in long term care (LTC) 
facilities using MarketScan Medicaid data.
29
  The study population consisted of residents 
aged 60 years and above. Twelve month COPD-related costs and all cause direct medical 
expenditure per beneficiary were $7,391 and $48,183, respectively. Largest cost 
component contributing to direct costs were LTC costs ($5,629) followed by pharmacy 
costs ($956), inpatient costs ($466) and outpatient costs ($341). 
 
Rascati and colleagues (2007) conducted a study to compare the effects of initial 
medication regimens for COPD on COPD-related and all-cause events (hospitalizations 
and/or emergency visits).
30
  The study was conducted on a historical cohort of Texas 
Medicaid beneficiaries aged 40-64 years with COPD-related costs, 24 months of 
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continuous Medicaid enrollment and at least 1 prescription claim for a combination 
product containing (fluticasone propionate + salmeterol), an inhaled corticosteroid 
(salmeterol) or ipatropium between the period two years. Results showed that only 
combination therapy was associated with a significantly lower risk for any COPD-related 
event and any all-cause event. 
 
Marton et al (2006) estimated COPD expenditures using Medicaid administrative 
claims data from California and Florida.
31
  The COPD cohort in each state included 
Medicaid recipients not dually eligible for Medicare and who were 40 years of age with 
at least one medical claim for COPD during 2001. The comparison cohort included 
patients with medical claims during 2001 for conditions other than chronic respiratory 
disease. Both the cohorts were matched by age, sex, and race. The estimated mean excess 
costs of COPD per patient were approximately $6,500 in California Medicaid and $5,200 
in Florida Medicaid. Both the Medicaid programs had similar attributable costs for 
COPD. 
 
Miller et al (2005) used national data from 2000 Medical Expenditure Panel 
Survey (MEPS) to estimate direct costs of COPD in the US from an all payer 
perspective.
27
  Study results showed that 1.7% of the patient population aged 45 years 
and above used medical resources and incurred expenditures related to COPD treatment. 
The mean attributable costs per patient were estimated at $2,507. More than half of these 
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costs were associated with hospitalizations. After adjusting for socio-demographic factors 
and smoking status, mean excess costs of COPD were $4,932 per patient. 
 
Mapel et al (2005) conducted a study to identify factors most predictive of future 
costs in COPD.
32
  A model that best determined the causes of cost variations in the 
disease was developed. The results were based on data extracted from Lovelace Health 
Plan, a health management organization that serves over 200,000 members in the New 
Mexico area of the US. Results showed that FEV1% is a significant but weak predictor of 
future health care resource utilization while prior hospitalization and home oxygen use, 
presence of co-morbid conditions and symptoms were better predictors of future costs. 
 
Study by Strassels and colleagues (2001) described the medical resource 
utilization and costs incurred by persons with COPD in the US.
33
  The National Medical 
Expenditure Survey (NMES) data for the year 1987 was used for the study. Among 
persons with COPD, mean per person direct medical expenditure was $6,469 out of 
which 68% was due to inpatient hospitalizations. 
 
Sharafkhaneh and colleagues (2010) compared health care utilization and costs 
among the US veterans with COPD and those without COPD (control group) using a 
retrospective matched-cohort study design.
34
  Data was obtained from the Department of 
Veteran Affairs (VA) which was integrated into the Veterans Integrated Service Network 
 29 
 
 
(VISN) 16 Database Warehouse for period of seven years. The seven year period 
prevalence was 8.2%. Patients with COPD had higher rates of inpatient and outpatient 
utilization and higher costs of care for respiratory conditions and all other conditions 
compared to controls. Also, COPD mean health care costs were 10 times higher than the 
population that did not have COPD. Results reflect the high prevalence of COPD and 
excess health care resource use in VA population which causes a substantial burden on 
federal government. Limitation of the study was that there was no information available 
on out of plan (non-VA) prescriptions. 
 
Akazawa et al (2008) estimated economic burden of undiagnosed COPD in the 
US by comparing health care utilization and costs between a cohort of newly diagnosed 
COPD patients.
35
  Trends for health care utilization and costs within a period of 36 
months prior to COPD diagnosis were determined. Patients with COPD had 1.5 times 
more inpatient and outpatient visits compared to patients without COPD. Incremental 
annual per person cost for inpatient/ emergency department visits and prescriptions were 
$550 and $401, respectively. Trend analysis demonstrated that health care utilization and 
costs slightly increased over time. Resources were consumed most frequently in the 
month before COPD diagnosis. 
 
Menzin et al (2008) estimated the excess costs of COPD for patients enrolled in a 
US Medicare managed care plan using Pharmetrics Patient Centric Database.
36
  The per 
patient cost of COPD ranged from $6,300 using an attributable cost approach. Excess 
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costs associated with COPD were $20,500. The results show the substantial cost burden 
from the Medicare perspective. The results, however, cannot be generalized to the overall 
Medicare program since the database included patients only in Medicare managed care 
plans. Out-of-pocket costs were not included, thus, from a societal perspective the study 
underestimated per patient cost of COPD. Also, the study did not directly address the 
aggregate burden from a national perspective. 
 
Tinkelman and colleagues (2005) explored health care utilization and burden of 
illness for younger patients with COPD (between ages 45-65) compared to older patients 
(older than age 65) using a US based managed care administrative claims database.
37
  It 
was  found that average cost of treating COPD among younger patients was higher 
($1,900-$2,000) compared to older patients (below $1,600). Facility services such as 
hospitalizations and emergency room (ER) visits were a major cost driver among all age 
groups with COPD.  
 
Darkow and colleagues (2008) estimated medical resource utilization and health 
care costs due to COPD among employed individuals.
38
  Health care claims data was 
analyzed within a one-year study period. Results were compared with individuals who 
did not have COPD. Total health care costs for employees with COPD were higher 
($4,916) compared to employees without COPD ($2,966). The greatest difference in 
terms of health care costs was evident in emergency visits among patients with COPD 
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($769 for patients with COPD and $489 for patients without COPD) who had a 2-3 times 
higher rate of ER visits compared to patients without COPD. 
 
Cost Studies in Asthma 
Kamble and Bharmal (2009) estimated the prevalence of asthma in 2004 using 
MEPS 2004 data and the direct incremental expenditures associated with asthma for two 
subpopulations; children (age < 18 years) and adults (age ≥ 18 years).28  The estimated 
prevalence for children and adults were 8.7% and 6.72%, respectively. It was found that 
children with asthma had 92% higher expenditures (mean annual incremental total 
expenditure = $1,004.6) compared to children without asthma. In adults, the mean annual 
incremental total expenditure was $ 2,077.5 per person. Largest proportion of the total 
expenditures was accounted by prescription medications which were estimated at $ 643.6 
in adults and $180.6 in children. Emergency room expenditures accounted for a small 
proportion of the total expenditure both age groups. 
 
Sapra and colleagues (2005) determined the net direct medical cost of asthma and 
evaluated the factors influencing the costs. The study used a case-control study design 
and North Carolina Medicaid data (May1996-April 1998).
39
  The net cost of asthma was 
$1,250 per patient. Prescription medications were associated with significantly higher 
cost burden. The results from this study are limited to a single state Medicaid program 
and cannot be generalized to the US population.  
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Pawar and Smith (2006) reported rates of asthma among African-Americans who 
received health care in West Virginia Medicaid program.
40
  Additionally, rates of asthma-
related medical services, prescriptions utilizations and costs to the Medicaid program for 
asthma-related care for these recipients were reported. A total of 635 African-Americans 
had asthma as their primary diagnosis. Majority of the population comprised of children 
who were under 21 years of age. Males who were of age 21 years and older had the 
highest rates of hospitalizations even though they accounted for the lowest proportion of 
the age-gender groups. Results showed that Medicaid paid the most for prescriptions and 
hospitalizations.  
 
Cisternas et al (2003) estimated the magnitude of direct and indirect costs of adult 
asthma from a societal perspective.
41
  A cross-sectional survey data from an ongoing 
community-based panel study was analyzed. Study subjects included adults with asthma 
who obtained care from a random sample of pulmonologists, allergists and family 
practitioners. Total annual costs of asthma per person averaged $4,912 out of which 65% 
were direct costs and 35% were indirect costs. Total direct medical costs averaged $2,697 
in which pharmaceuticals were the largest cost contributor followed by hospital 
admissions and ER visits. The results of the study are limited to State of California which 
has higher number of managed care settings which could have a downward pressure on 
costs. 
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Birnbaum et al (2001) estimated the overall costs of asthma to a major employer 
in US using an economic profile for asthma care that was developed using a case-control 
analysis.
42
  Annual per capita employer expenditures for patients with asthma was $535 
which was approximately 2.5 times higher than those without asthma. Total costs were 
approximately 3 times higher among asthmatic employees with disabilities compared to 
non-asthmatic employees. Medical care component was the largest cost component 
(59%) followed by prescription drugs (25%) and work loss (16%). Incremental costs of 
asthma were calculated to be $3,265. Costs calculated by this study cannot be compared 
to general population since a cost of illness method was not used. 
 
Weiss and colleagues (2000) demonstrated trends in cost of illness for asthma in 
the US from 1985 to 1994 using health care survey data available from National Center 
for Health Statistics.
43
  In 1994, the total cost of asthma in the US was $10.7 billion 
dollars. There was a 54.1% increase in cost estimates from 1985 to 1994. Medications 
represented the largest cost component (40.1%) as demonstrated in previous studies. 
There was also a decline in estimated costs per affected person with asthma (3.4% 
decline) during this time period. The study provides evidence of increasing national 
prevalence and cost burden of asthma. 
 
Malone and colleagues (2000) examined characteristics of patients with asthma 
who accounted for 80% of national expenditures in 1994 US dollars using 1987 National 
Medical Expenditure Survey (NMES).
44
  The study population was divided into two 
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groups. High-cost group represented 20% of expenditures. It was found that high cost 
group had individuals who rated their health as poor/fair. 
 
Stroupe and colleagues (1999) calculated health care costs within a 1 year period 
among inner city asthma patients.
45
  Direct costs associated with asthma was $2.5 million 
dollars out of which 35.5% was due to asthma management. Largest cost component 
contributing to direct costs was outpatient visits. 
 
Leigh and colleagues (2002) estimated the number of annual deaths in addition to 
the direct and indirect costs of occupational COPD and asthma.
46
  Analysis was 
conducted on national data sets collected by Center of National Health Statistics. Results 
demonstrate that costs attributable to COPD were $5.0 billion compared to $1.6 billion in 
asthma.  In COPD, direct costs accounted for 56% of the total cost. In asthma, directs 
costs were substantially higher compared to COPD accounting for 74% of total costs.  
 
This chapter reviews information on the direct cost estimates available for COPD 
and asthma. The studies presented in this review also provide information on the major 
cost contributors in terms of medical services utilized by individuals who suffer from 
these conditions. These studies, however, do not provide any cost estimates from an all 
payer perspective. Also, the cost estimates provided cannot be generalized to the US 
population since only state level estimates were computed. The present study aims to 
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report the direct incremental total health care expenditure for COPD and asthma. The 
goal is also to identify socio-demographic characteristics that would be good predictors 
for health care expenditures associated with both these diseases. 
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CHAPTER THREE 
METHODS 
  
The previous chapter gave a summary of the cost of illness studies pertaining to 
COPD and asthma that have been reported in the literature. This chapter will describe the 
data source that was used to achieve the research objectives of this study. The chapter 
will also describe the methods and statistical procedures used to complete each study 
objective. 
 
Data Source  
 
The 2007 Medical Expenditure Panel Survey (MEPS), a nationally representative 
sample of ambulatory population in the US, was used as the data source for the analyses. 
The MEPS is conducted annually since 1996 and is co-sponsored by the Agency for 
Health care Research and Quality (AHRQ) and the National Center for Health Statistics 
(NCHS). It provides nationally representative estimates of health care use, spending, 
sources of payment, and insurance coverage for the US civilian non-institutionalized 
population.  
 
The survey administered by MEPS is comprised of two major components: the 
Household Component (HC) and the Insurance Component (IC). The HC provides data 
from individual households and their members, which is supplemented by data from the 
medical providers. The HC provides data from a sample of families and individuals in 
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selected communities across the US. These communities are drawn from a nationally 
representative subsample of households that participated in the prior years’ National 
Health Interview Survey that is conducted by the National Center of Health Statistics. 
Through an interview process, MEPS collects data from each household that provides 
detailed information on demographic characteristics, health conditions, health status, use 
of medical services, charges and sources of payments, access to care, satisfaction with 
care, health insurance coverage, income and employment. Data for the HC is available 
for download on the MEPS website. The IC is a separate survey of employers that 
provides data on employer-based health insurance.  Other components include the 
Medical Provider Component (MPC) linked to the household survey, and the Nursing 
Home component (NHC). The MPC surveys hospitals, physicians, home health care 
providers, and pharmacies that were identified by the MEPS-HC respondents. Data from 
MPC is used to supplement or replace data in the MEPS-HC and therefore, is not 
available for public release. The NHC surveys a sample of nursing homes and its 
residents nationwide and provides data on the characteristics of the facilities offered, 
expenditures and sources of payment and individual resident characteristics such as age, 
income and insurance coverage information. Since the data from this component is highly 
confidential, it can be found only at the Data Center located at AHRQ or at one of the 
Census Bureau’s Research Data Center.  
 
The 2007 full year consolidated data file and the medical conditions file from the 
HC were used for this study. Data from the two files were extracted. The two files were 
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then merged using the International Classification of Diseases, 9
th
 revision (ICD-9-CM 
codes) to form a final dataset for analyses. 
 
Data Extraction 
 
The 2007 consolidated full year file and medical conditions file were downloaded 
from the MEPS website.
46
  The files were unzipped and decompressed to extract the data 
in ASCII format. The ASCII files were then converted to Predictive Analytical Software 
(PASW) version 18.0 with the help of SPSS load programs for each file which were also 
downloaded from the MEPS website.
47 
 The consolidated full year file and medical 
conditions file were merged using the ICD-9-CM codes for COPD (491.0, 492.0 and 
496.0) and for asthma (493.0, 493.1 and 493.2) to form a final dataset that were used for 
the analyses.  
 
Study Population 
 
The sample size consisted of four cohorts that were identified from the target 
population (MEPS-2007 household data file) using ICD-9-CM codes. Respondents with 
ICD-9-CM codes 491.0, 492.0, and 496.0 were classified as individuals with COPD. 
Individuals having an ICD-9 code other than 491.0, 492.0, and 496.0 were classified as 
individuals without COPD. Respondents with ICD-9 codes 493.0, 493.1 and 493.2 were 
classified as individuals with asthma. Individuals having an ICD-9 code other than 493.0, 
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493.1, and 493.2 were classified as individuals without asthma. The analyses were 
conducted on individuals aged 18yearsand older.  
 
Independent variables 
 
Presence of COPD or asthma 
The present study constructed two main independent variables; the presence of 
COPD and the presence of asthma. MEPS provided the medical condition of the 
respondents in the form of one variable which is named ICD9CODX in the dataset. We 
recoded this variable into two different variables with the help of ICD-9 codes. The 
recoded variables were called “COPD” and “asthma” and had two categories “Yes” and 
“No” which indicated the presence or absence of the disease.  
Age 
The respondents reported their age in years during the MEPS interview. This 
variable was present in a continuous form. It was categorized into five different 
categories. These categories were 18-28 years, 29-38 years, 39-48 years, 49-58 years and 
59 years and above. Age was categorized in order to study the differences in expenditures 
in COPD and asthma in different age groups. 
Gender 
The gender variable was used as an indicator of sex of the respondents and was 
categorized as male and female. 
 40 
 
 
Race 
  Race was present as a categorical variable with five categories: White, African-
American, Native American, Asian, Hawaiian and other (this included individuals who 
reported multiple races). 
Income 
Income in MEPS is defined as the total person-level income which is the sum of 
all income components. This variable was present in a continuous form. In the present 
study, income was categorized into four categories: less than $20,000, $20,000-$39,999, 
$40,000-$59,999, and greater than $60,000. This variable was categorized to help us 
identify how prevalence and expenditures related with COPD and asthma vary with 
different income levels.  
Insurance Status 
MEPS summarized the health insurance information into one single variable 
(INSCOV07). This variable provides information on the insurance status of the 
respondent. The variable has three different categories: private insurance (insurance 
provided through employment, TRICARE), public insurance (Medicaid, Medicare) and 
uninsured.  
Marital Status 
Respondents reported their current marital status during the interview. This 
variable was present in six categories in the MEPS data file. These categories were 
married, widowed, divorced, separated, never married and inapplicable (for respondents 
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under age 16 years). In the present study, this variable was categorized into two 
categories: presently married and not married. 
Geographic region  
This variable was present in four categories representing the four regions of the 
US: Northeast, Midwest, South and West. 
 
Outcome Variables 
 
There were six dependent variables in the analyses. These included:  
Total health care expenditure:  
The total health care expenditure is the sum of expenditures associated with the care 
received in different service categories (office-based, outpatient, inpatient, emergency 
room, prescriptions, and other services). 
Total office-based expenditures 
The total office-based expenditure is defined as expenditures associated with all medical 
provider visits, physician visits, and non physician visits in office-based settings. 
Total outpatient expenditures 
The total outpatient expenditure is defined as expenditures associated with all medical 
provider visits, physician visits, and non physician visits in outpatient. 
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Total inpatient expenditures 
The total inpatient expenditure is defined as expenditures associated with hospital 
inpatient stays. 
Total emergency room expenditures 
The total emergency room expenditure is defined as expenditures associated with the 
emergency room visits reported. 
Total prescription expenditures 
 The total prescription expenditure is defined as sum of all amounts paid out-of-pocket 
and by third party payers for each prescription purchased.  
All expenditures were provided as the sum of all direct payments for care provide 
during 2007, including out-of-pocket payments and payments by private insurance, 
Medicare, Medicaid, and other sources.  
 
Data Analysis 
 
Data was analyzed using PASW version 18.0. In order to produce national 
estimates from MEPS survey data, the MEPS survey design complexities such as sample 
stratification, clustering, multiple stages of selection, survey non-response and 
disproportionate sampling need to be taken into account during data analysis. Survey 
design complexities can be accounted for by applying survey weights and using an 
appropriate method to derive standard errors associated with the weighted estimates. 
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MEPS used Taylor-series linearization method to estimate standard errors for weighted 
survey estimates. The MEPS public use files provide appropriate variables to calculate 
weighted estimates.  
Objective 1: National Prevalence of COPD and Asthma. 
Frequencies for individuals with a diagnosis of COPD (ICD-9 codes 491.0, 492.0, 
496.0) and a diagnosis of asthma (ICD-9 codes 493.0, 493.1 and 493.2) were analyzed 
and reported. Survey weights were applied to generate a national estimate for the 
prevalence COPD and asthma. 
Objective 2: Demographic characteristics of individuals with COPD and individuals with 
asthma. 
A descriptive analysis was conducted for individuals with a diagnosis of COPD 
and a diagnosis of asthma. The mean age was reported and the frequencies for age, 
gender, race, income, insurance status, marital status and region were analyzed. A cross 
tabulation was also conducted to compare demographic characteristics in individuals with 
COPD and individuals without COPD. Similarly, a cross tabulation for individuals with 
asthma and without asthma was conducted to compare demographic characteristics. 
Objective 3: Mean Expenditures for total health care expenditures, total office-based 
expenditure, total outpatient expenditure, total inpatient expenditure, total emergency 
room expenditure and total prescription expenditure in individuals with COPD and 
individuals with asthma. 
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To calculate the mean expenditures in each service category, a separate dataset 
was created that only contained cases with individuals who had a COPD diagnosis. 
Descriptive analysis was conducted and the mean total health care expenditure, mean 
total office-based expenditure, mean total outpatient expenditure, mean total inpatient 
expenditure, mean total emergency room expenditure and mean total prescription 
expenditure were reported. Similarly, another dataset was created that only contained 
cases of individuals who had an asthma diagnosis. Descriptive analysis was conducted 
and the mean total health care expenditure, mean total office-based expenditure, mean 
total outpatient expenditure, mean total inpatient expenditure, mean total emergency 
room expenditure and mean total prescription expenditure were reported for individuals 
with asthma.  
Objective 4: Identify predictors for total health expenditures, total office-based 
expenditure, total outpatient expenditure, total inpatient expenditure, total emergency 
room expenditure and total prescription expenditure in individuals with COPD. 
A multiple linear regression model was used for total health care expenditures, 
total office-based expenditure, total outpatient expenditure, total inpatient expenditure, 
total emergency room expenditure and total prescription expenditure. In order to carry 
out a linear regression, the data should meet the assumption of linearity, normality, 
homoscedasticity and multicollinearity. To test the data for normality, a histogram was 
created using the residual values of the dependent variable. It was found that the data was 
slightly skewed towards the left. Since the sample size used in this study was large, a 
regression analysis with slightly skewed data could still give us reliable results. To check 
for linearity, the independent variables were plotted against the dependent variables using 
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a scatterplot. A linear relation was observed in the scatterplot. To check for 
homoscedasticity, a residual plot was created and it was observed that the variance was 
constant across different levels of the dependent variable. Finally, multicollinearity was 
checked by observing the collinearity diagnostics. It was noticed that the Variance 
inflation factor (VIF) was less than 10 and the tolerance level was between 0 and 1 which 
confirmed that the independent variables were not correlated with each other. The 
presence or absence of COPD was the main independent variable. Absence of COPD was 
used as a reference category. Other covariates included in the analyses were age, gender, 
race, income, insurance status, marital status and geographic region. Dummy variables 
were created for variables that had more than two categories. In regression analysis, a 
dummy variable is a variable that takes the value of 0 or 1 in order to indicate the absence 
or presence of some categorical effect that may be expected to shift the outcome.
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Variables for which dummy variables were created were: age, race, income, insurance 
coverage and region. The “Enter” method for multiple linear regression was used for the 
analysis. The “Enter” method enters all the variables in the regression model at the same 
time.
49 
 Unlike the “stepwise” method, the “enter” method allows the researcher to select 
the predictor variables that make up the model. In the “stepwise” method, SPSS enters 
the variables in a sequence and only retains the variable that contributes to the model.  
Significant predictors of health care expenditures would be variables with a significant p-
value (defined as p≤0.05).  This study did not include disease severity and disease co-
morbidity in the model which could affect the accuracy of the model. MEPS data does 
not report disease severity while disease comorbidity was assumed to be the same 
between the disease cohort and the non-disease cohort and thus was not included. The 
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following equation represents the regression model used in this study to predict health 
care expenditures. 
 
Expenditure= β0 + β1 Presence of COPD+ β2Age+ β3Gender+ β4Race+ β5Income+ 
β6Insurance Status+ β7Marital Status+ β8Geographic Region 
Objective 5: Calculate a National Estimate for Total Incremental Health care 
Expenditure of treating COPD 
To calculate a national estimate for the incremental health care expenditure for 
treating COPD, the prevalence of COPD was multiplied by the estimated incremental 
expenditure computed from the regression analysis. 
Objective 6: Identify predictors for total health care expenditures, total office-based 
expenditure, total outpatient expenditure, total inpatient expenditure, total emergency 
room expenditure and total prescription expenditure in individuals with asthma. 
As described in Objective 4, a multiple linear regression model was used for total 
health care expenditures, total office-based expenditure, total outpatient expenditure, total 
inpatient expenditure, total emergency room expenditure and total prescription 
expenditure. The presence or absence of asthma was the main independent variable. 
Here, absence of asthma was used as a reference category. Other covariates included in 
the analyses were age, gender, race, income, insurance status, marital status and 
geographic region. Dummy variables were created for variables that had more than two 
categories just as described in Objective 4. The “Enter” method for multiple linear 
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regression was used for the analysis. Significant predictors of health care expenditures 
would be variables with a significant p-value (defined as p≤0.05). The following equation 
represents the regression model used in this study to predict health care expenditures. 
 
Expenditure= β0 + β1 Presence of Asthma+ β2Age+ β3Gender+ β4Race+ β5Income+ 
β6Insurance Status+ β7Marital Status+ β8Geographic Region 
Objective 7: Calculate a national estimate for the total incremental health care 
expenditure of treating asthma 
As described in Objective 5, a national estimate for the incremental health care 
expenditure for treating asthma was calculated by multiplying the prevalence of asthma 
by the estimated incremental expenditure computed from the regression analysis. 
 
This chapter described the data source that was used in this study and the 
statistical procedures that were used in order to generate statistical estimates for each 
research objective that we have mentioned. The next chapter will present the results for 
each of the study objectives.  
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CHAPTER FOUR 
RESULTS 
 
Objective 1: National prevalence of COPD and asthma  
A descriptive analysis was conducted to generate frequencies for individuals who 
had a diagnosis of COPD and individuals who had a diagnosis of asthma. It was found 
that 1,290,775 individuals had a diagnosis of COPD in the year 2007 according to the 
MEPS weighted data. This accounts for 0.40% of the population surveyed. It was also 
found that 28,332,791 people were diagnosed with asthma. This accounts for 9.50% of 
the individuals that were surveyed in MEPS based on the weighted data 
Objective 2:  Demographic characteristics of individuals with COPD and individuals 
with asthma 
A descriptive analysis was conducted to generate frequencies for the socio-
demographic characteristics of individuals with COPD, individuals with asthma and 
individuals without COPD and asthma.  COPD was found to be more prevalent among 
males. COPD was also more common in the age group of ≥59 years. Mean age among 
individuals with COPD was 38.69 years. In terms of race and ethnicity, COPD was 
predominant among whites (74.48%).  Furthermore, individuals with an income of less 
than $20,000 per year were more likely to have COPD. The condition was also found to 
be more prevalent in the Southern region of the US (37.21%). Individuals with COPD 
were most likely to have private insurance (65.15%). Table 3 displays the socio-
demographic characteristics for individuals with COPD and without COPD for 
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comparison and Table 4 displays the weighted data for individuals with COPD showing 
the socio-demographic disparities.  
 
Asthma was found to be more prevalent among females and was predominant 
among the white population (69.86%) followed by African Americans (22.10%). Asthma 
was more common among the age groups of 18-22 years (21.38%), and ≥59 years 
(25.36%). The mean age among patients with asthma was 35.86 years. Similar to COPD, 
asthma was more prevalent in the southern region of the US (37.90%). Predominant 
population with asthma held private insurance coverage (53.36%). In addition, the 
individuals with asthma were not married and were in the income level group of less than 
$20,000. Table 5 gives the socio-demographic characteristics among individuals with 
asthma and without asthma for comparison and Table 6 displays the weighted data for 
individuals with asthma showing socio-demographic disparities. 
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Table 3. Socio-demographic characteristics in individuals with COPD and individuals 
without COPD (un-weighted data) 
 
  COPD No COPD 
Variable Level N (%) N (%) 
Age (years) 18-28 16 (16.49) 4,525 (20.87) 
 29-38 21 (21.65) 3,947 (18.20) 
 39-48 15 (15.46) 4,155 (19.16) 
 49-58 12 (12.37) 3,862 (17.81) 
 ≥59 33 (34.20) 5,196 (23.96)  
 
Age (years, 
Mean+SD) 
 38.69±24.71 38.69±24.73 
    
Gender Male 68 (51.52) 14,749 (47.84) 
 Female 64 (48.48) 16,083 (52.16) 
    
Race/Ethnicity White 97 (73.48) 22,978 (74.53) 
 African American 21 (15.91) 5,383 (17.46) 
 Native American 1 (0.76) 277 (0.90) 
 Asian 7 (5.30) 1,435 (4.65) 
 Hawaiian/Pacific Islander 2 (1.52) 107 (0.35) 
 Other 4 (3.03) 652 (2.11) 
    
Region  Northeast 20 (15.50) 4,497 (14.69) 
 Midwest 30 (23.26) 6,194 (20.23) 
 South 48 (37.21) 11,651 (38.05) 
 West  31 (24.03) 8,276 (27.03) 
    
Marital Status Presently Married 59 (44.70) 11,985 (38.88) 
 Not Married 73 (55.30) 18,837 (61.12) 
    
Income <$20,000 78 (60.00) 19,379 (63.38) 
 $20,000-$39,999 28 (21.54) 5,764 (18.85) 
 $40,000-$59,000 16 (12.31) 2,732 (8.94) 
 ≥$60,000 8 (6.15) 2,700 (8.83) 
    
Insurance Coverage Private 86 (65.15) 17,249 (55.95) 
 Public 27 (20.45) 8,467 (27.46) 
 Uninsured 19 (14.39) 5,116 (16.59) 
SD = Standard Deviation 
N =  Number of individuals 
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Table 4. Socio-demographic characteristics in individuals with COPD and individuals 
without COPD (weighted data) 
  COPD No COPD 
Variable Level N (%) N (%) 
Age (years) 18-28 158,700 (16.60) 45,538,265 (20.31) 
 29-38 161,025 (16.85) 39,794,107 (17.75) 
 39-48 179,160 (18.74) 42,518,871 (18.97) 
 49-58 107,217 (11.22) 40,351,972 (18.00) 
 ≥59 349,818 (36.59) 55,979,853 (24.97) 
 
Age (years, 
Mean+SD) 
 38.69±24.71 36.50±22.60 
    
Gender Male 692,093 (53.62) 146,936,724 (48.97) 
 Female 598,682 (46.38) 153,081,650 (51.02) 
    
Race/Ethnicity White 1,046,598 (81.08) 240,766,140 (80.25) 
 African American 136,045 (10.54) 37,172,762 (12.39) 
 Native American 222,83 (1.73) 2,483,414 (0.83) 
 Asian 30,729 (2.38) 13,089,256 (4.36) 
 Hawaiian/Pacific Islander 18,468 (1.43) 1,018,350 (0.33) 
 Other 36,651 (2.84) 5,488,452 (1.83) 
    
Region  Northeast 262,668 (20.93) 53,900,129 (18.10) 
 Midwest 304,502 (24.26) 65,114,207 (21.87) 
 South 268,312 (21.38)  69,464,172 (23.33) 
 West  419,473 (33.43) 109,245,697 (36.69) 
    
Marital Status Presently Married 561,439 (43.50) 123,010,022 (41.00) 
 Not Married 729,336 (56.50) 176,990,543 (59.00) 
    
Income <$20,000 665,912 (52.04) 163,718,543 (55.05) 
 $20,000-$39,999 309,326 (24.18) 62,654,861 (21.07) 
 $40,000-$59,000 193,234 (15.10) 34,866,672 (8.94) 
 ≥$60,000 111,041 (8.68) 36,180,926 (11.72) 
    
Insurance Coverage Private 972,443 (75.34) 200,913,860 (65.97) 
 Public 170,713 (13.23) 59,101,331 (19.70) 
 Uninsured 147,619 (11.44) 40,003,184 (13.33) 
SD = Standard Deviation 
N = Number of individuals 
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Table 5. Socio-demographic characteristics of individuals with asthma and individuals 
without asthma (un-weighted data)    
  Asthma No Asthma 
Variable Level N (%) N (%) 
Age (years) 18-28 420 (21.38) 4,091 (20.83) 
 29-38 324 (16.50) 3,623 (18.45) 
 39-48 362 (18.43) 3,785 (19.27) 
 49-58 360 (18.33) 3,476 (17.70) 
 ≥59 498 (25.36) 4,666 (23.76) 
 
Age (years, 
Mean+SD) 
 35.86±22.19 36.74±22.51 
    
Gender Male 1254 (42.51) 13,387 (48.41) 
 Female 1696 (57.94) 14,267 (51.60) 
    
Race/Ethnicity White 2061 (69.86) 20,753 (75.05) 
 African American 652 (22.10) 4,674 (16.90) 
 Native American 26 (0.88) 250 (0.90) 
 Asian 92 (3.12) 1,341 (4.85) 
 Hawaiian/Pacific Islander 15 (0.51) 93 (0.34) 
 Other 104 (3.53) 543 (1.96) 
    
Region  Northeast 498 (16.93) 3,988 (14.45) 
 Midwest 616 (20.94) 5,568 (20.18) 
 South 1,115 (37.90) 10,500 (38.05) 
 West  713 (24.24) 7,539 (27.32) 
    
Marital Status Presently Married 931 (31.56) 10,977 (39.70) 
 Not Married 2,019 (68.44) 16,676 (60.30) 
    
Income <$20,000 2,014 (68.74) 17,170 (62.62) 
 $20,000-$39,999 493 (16.83) 5,242 (19.12) 
 $40,000-$59,000 207 (7.06) 2,526 (9.21) 
 ≥$60,000 216 (7.37) 2,482 (9.05) 
    
Insurance Coverage Private 1,574 (53.36) 15,649 (56.59) 
 Public 1,083 (36.71) 7,283 (26.34) 
 Uninsured 293 (9.93) 4,722 (17.08) 
SD = Standard Deviation 
N = Number of individual
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Table 6. Socio-demographic characteristics of individuals with asthma and individuals 
without asthma (weighted data). 
  Asthma No Asthma 
Variable Level N (%) N (%) 
Age (years) 18-28  4,236,528 (20.63) 41,299,239 (20.29) 
 29-38 3,684,131 (17.94) 36,180,323 (17.78) 
 39-48 3,790,806 (18.46) 38,768,181 (19.05) 
 49-58 3594,740 (17.50) 36,624,642 (18.00) 
 ≥59 5,232,861 (25.48) 50,636,121 (24.88) 
 
Age (years, 
Mean+SD) 
 38.86±22.19 36.58±22.65 
    
Gender Male 11,980,777 (42.23) 134,265,119 (49.70) 
 Female 16,352,014 (57.71) 135,902,133 (50.30) 
    
Race/Ethnicity White 22,180,487 (78.29) 217,360,695 (80.45) 
 African American 4,168,926 (14.71) 32,712,249  (12.11) 
 Native American 221,685 (0.78) 2,276,428 (0.84) 
 Asian 802,808 (2.83) 12,257,943 (4.54) 
 Hawaiian/Pacific Islander 150,359 (0.53) 886,458 (0.33) 
 Other 808,526 (2.85) 4,673,479 (1.73) 
    
Region  Northeast 5,458,281 (19.32) 48536895 (18.01) 
 Midwest 6,044,183 (21.39) 59,131,757 (21.94) 
 South 6,311,475 (22.34) 63,185,979 (23.44) 
 West  10,440,855 (36.95) 98,707,549 (36.62) 
    
Marital Status Presently Married 10,222,557 (36.08) 112,273,630 (41.56) 
 Not Married 18,110,234 (63.92) 157,875,814 (58.44) 
    
Income <$20,000 16,718,859 (59.41) 145,690,458 (54.40) 
 $20,000-$39,999 5,774,556 (20.52) 56,686,861 (21.17) 
 $40,000-$59,000 2,735,635 (9.72) 32,177,685 (12.01) 
 ≥$60,000 2,910,450 (10.34) 33,259,366 (12.42) 
    
Insurance Coverage Private 18,581,620 (65.58) 182,002,972 (67.37) 
 Public 7,252,802 (25.60) 50,937,571 (18.85) 
 Uninsured 2,498,369 (8.82) 37,226,709 (13.78) 
SD= Standard Deviation 
N= Number of individuals
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Objective 3: Mean total health care expenditures, mean office-based expenditures, mean 
outpatient expenditures, mean inpatient expenditures, mean emergency room 
expenditures and mean prescription expenditures in individuals with COPD and in 
individuals with asthma. 
A separate dataset was created that contained only the cases with individuals who 
had a diagnosis of COPD. Using the newly created dataset, a descriptive analysis was 
conducted to determine mean health care expenditures in each service category. Table 5 
displays the results of the descriptive analysis. In individuals with COPD, mean total 
health care expenditures were $4,773.63. Among service categories, office-based 
expenditures were highest ($1,760.25) followed by prescription expenditures ($1,195.99) 
in individuals with COPD. Mean total health care expenditures associated with asthma 
were $6,023.44. Inpatient expenditures were highest ($1,996.28) among patients with 
asthma followed by prescription expenditures ($1,499.89). 
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Table7. Mean expenditures in different service category per person. 
 
 COPD Asthma 
Total Health care Expenditures $4,773.63 $6,023.44 
Total Office Based Expenditures $1,760.25 $1,320.99 
Total Outpatient Expenditures $334.96 $397.76 
Total Inpatient Expenditures $906.91 $1,996.28 
Total Emergency Room Expenditures $84.21 $191.25 
Total Prescription Expenditures $1,195.99 $1,499.89 
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Objective 4: Identifying the predictors for total health care expenditures, office-based 
expenditures, outpatient expenditures, inpatient expenditures, emergency room 
expenditures and prescription expenditures in patients with COPD. 
Multivariate regression was conducted to identify the incremental cost in COPD 
and identify factors that predict health care expenditures in COPD. There were six 
different regression models used since there were six different service categories for 
health care expenditures. The dependent variables were the health care expenditure in 
each service category: total health care expenditure, total office based expenditure, total 
outpatient expenditure, total inpatient expenditure, total emergency room expenditure and 
total prescription expenditure. The main independent variable in the regression model 
was the presence or absence of COPD. Table 8 displays the results for the regression 
analysis that was conducted for total health care expenditures for patients with COPD.  It 
was found that there was an incremental cost of $1,739.23 associated with COPD. Other 
variables that were significant predictors for total health care expenditures in COPD 
included gender, age, insurance coverage, marital status and region. Males had $444.89 
lower total health care expenditures than females (reference category). The age groups 
49-58 years and ≥59 years had significantly higher health care expenditures ($3,125.15 
and $6,172.88, respectively) compared to the age group 29-38 years (reference category).  
Also, individuals who held private insurance or public insurance had higher health care 
expenditures ($1,945.65 and $2,521.12, respectively) compared to the uninsured 
individuals (reference category). Individuals, who were presently married, incurred 
$419.22 higher health care expenditures compared to individuals who were not married. 
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The western region of the US had $643.90 lower health care expenditures compared to 
the southern region (reference category).  
 
Regression results for total office-based expenditures are shown in Table 9. 
Variables that were found significant in the regression model were presence of COPD, 
gender, age, income level, insurance coverage, marital status and region in the US. It was 
found that COPD was associated with an incremental expenditure of $610.55. Males with 
COPD had $164.34 lower office-based expenditures compared to females with COPD. 
Age groups that had significantly higher office-based expenditures compared to the 
reference category were 49-58 years and ≥59 years. These age groups were associated 
with $410.57 and $786.56 higher office-based expenditures, respectively. Individuals 
with an income level of $40,000-$59,999 and ≥$60,000 had higher expenditures 
compared to <$20,000 (reference category). Office-based expenditures in these income 
level groups were $101.58 and $117.87, respectively. Furthermore, individuals with 
private insurance or public insurance incurred an incremental office-based expenditure of 
$382.61 and $303.12, respectively compared to the individuals who were uninsured 
(reference category). Individuals who were presently married had $133.33 higher office-
based expenditures compared to individuals who were not married. It was also noticed 
that individuals with COPD in the mid-west region of the incurred higher office-based 
expenditures ($98.85 higher) compared to the individuals in the southern region 
(reference category).
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Table 8. Predictors for total health care expenditures in 2007 for COPD 
 
Regression Model   B SE CI  Sig. (p) 
Variables  Levels   Lower  Upper  
Bound Bound 
        
Presence of condition  COPD 1,739.23 941.64 -106.43 3,584.88 .065 
  No COPD†      
        
Gender  Male -444.88 123.97 -687.87 -201.90 .000* 
  Female†      
        
Age in years  18-28 199.38 189.48 -172.00 570.76 .293 
  29-38 383.40 209.42 -27.06 793.87 .067 
  39-48†      
  49-58 3,125.15 211.50 2,710.61 3,539.70 .000* 
  ≥59 6,172.88 187.12 5,806.13 6,539.64 .000* 
        
Race  White 173.73 169.88 -159.24 506.71 .306 
  African American†      
  Native American 69.85 665.29 -1,234.14 1,373.84 .916 
  Asian -597.69 331.57 -1,247.59 52.20 .071 
  Hawaaiian 878.40 1,051.18 -1,181.94 2,938.75 .403 
  Other 547.31 449.26 -333.27 1,427.88 .223 
        
Income   <$20,000†      
  $20,000-$39,999 -27.15 176.23 -372.56 318.26 .878 
  $40,000-$59,999 103.90 237.41 -361.44 569.23 .662 
  ≥60,000 -195.631 243.85 -673.58 282.322 .422 
        
Insurance Coverage  Private 1,945.65 180.66 1,591.55 2,299.75 .000* 
  Public 2,521.12 201.62 2,125.94 2,916.30 .000* 
  Uninsured†      
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Regression Model   B SE CI  Sig. (p) 
Variables  Levels   Lower  Upper  
Bound Bound 
Marital Status  Presently Married 419.22 146.70 131.68 706.77 .004* 
  Not Married†      
        
Region  Northeast -212.17 190.18 -584.93 160.58 .265 
  Midwest 146.76 171.12 -188.64 482.16 .391 
  South†      
  West -643.90 160.32 -958.13 -329.68 .000* 
        
Multiple Linear Regression Analysis-Enter Method, all variables entered. *Significance is at 0.05 level. 
Dependent variable: Total Health care Expenditure 
†=Reference Category 
 B = Regression Coefficient; SE = Standard Error of the regression coefficient, CI = Confidence Interval, Sig = Significance  
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Table 9. Predictors for total office-based expenditures in 2007 for COPD 
 
Regression Model   B SE CI  Sig. (p) 
Variables  Levels   Lower  Upper  
Bound Bound 
        
Presence of condition  COPD 610.55 190.28 237.61 983.50 .001* 
  No COPD†      
        
Gender  Male -164.35 25.05 -213.45 -115.25 .000* 
  Female†      
        
Age in years  18-28 41.82 38.29 -33.23 116.86 275 
  29-38 55.81 42.32 -27.13 138.75 .187 
  39-48†      
  49-58 410.57 42.74 326.80 494.34 .000* 
  ≥59 786.56 37.81 712.45 860.67 .000* 
        
Race  White 42.31 34.33 -24.98 109.59 .218 
  African American†      
  Native American 145.35 134.43 -118.15 408.84 .280 
  Asian -96.87 67.00 -228.19 34.45 .148 
  Hawaaiian -146.41 212.41 -562.74 269.92 .491 
  Other 55.33 90.78 -122.61 233.27 .542 
        
Income   <$20,000†      
  $20,000-$39,999 21.86 35.61 -47.94 91.65 .539 
  $40,000-$59,999 101.58 47.97 7.55 195.61 .034* 
  ≥60,000 117.87 49.27 21.29 214.45 .017* 
        
Insurance Coverage  Private 382.61 36.51 311.05 454.16 .000* 
  Public 303.20 40.74 223.34 383.05 .000* 
  Uninsured†      
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Regression Model   B SE CI  Sig. (p) 
Variables  Levels   Lower  Upper  
Bound Bound 
Marital Status  Presently Married 133.33 29.64 75.23 191.43 .000* 
  Not Married†      
        
Region  Northeast 9.80 38.43 -65.53 85.12 .799 
  Midwest 98.85 34.58 31.08 166.62 .004* 
  South†      
  West -20.96 32.40 -84.46 42.53 .518 
        
Multiple Linear Regression Analysis-Enter Method, all variables entered. *Significance is at 0.05 level. 
Dependent variable: Total Office-Based Expenditure 
†=Reference Category  
B = Regression Coefficient; SE = Standard Error of the regression coefficient, CI= Confidence Interval, Sig= Significance Level 
 
 
 
 62 
 
 
Regression results for total outpatient expenditures in COPD are displayed in 
Table 10. Variables that would significantly predict outpatient expenditures in COPD 
include gender, age, income level, insurance coverage, marital status and region in the 
US. Results show that presence of COPD in individuals is associated with an incremental 
outpatient expenditure of $172.32. However, this value was not statistically significant 
because the p-value was >0.05. Males had lower expenditures compared to females 
($42.57 lower). Individuals in the age groups 49-58 years and ≥59 years had higher 
outpatient expenditures than individuals in the age group 39-48 years (reference 
category). The outpatient expenditures in the age group 49-58 years was $273.39 and in 
the age group >59 years was $392.76, respectively. All income levels had statistically 
significant higher outpatient expenditures compared to the income level of <$20,000. 
Incremental outpatient expenditures associated with individuals who had an income level 
of $20,000-$39,999, $40,000-$59,999 and ≥$60,000 were $81.68, $154.22 and $87.52, 
respectively. Individuals with private insurance incurred an incremental outpatient 
expenditure of $175.71 and individuals with public insurance incurred an incremental 
outpatient expenditure of $99.23 compared to individuals who were uninsured (reference 
category). Also, individuals who were presently married had $76.45 higher outpatient 
expenditures compared to individuals who were not married. The northeast region and 
the mid-west region in the US were associated with a statistically significantly higher 
expenditure ($66.78 and $145.22, respectively) compared to the southern region 
(reference category).
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Table 10. Predictors for total outpatient expenditures in 2007 for COPD 
 
Regression Model   B SE CI  Sig. (p) 
Variables  Levels   Lower  Upper  
Bound Bound 
        
Presence of condition  COPD 172.32 167.18 -155.36 500.01 .303 
  No COPD†      
        
Gender  Male -42.57 22.01 -85.72 .57 .053* 
  Female†      
        
Age in years  18-28 -44.88 33.64 -110.82 21.05 .182 
  29-38 -50.13 37.18 -123.00 22.75 .178 
  39-48†      
  49-58 273.39 37.55 199.79 346.99 .000* 
  ≥59 392.76 33.22 327.64 457.87 .000* 
        
Race  White 44.16 30.16 -14.96 103.28 .143 
  African American†      
  Native American 15.59 118.12 -215.92 247.11 .895 
  Asian -108.23 58.87 -223.62 7.16 .066 
  Hawaaiian 126.46 186.63 -239.35 492.26 .498 
  Other 31.76 79.76 -124.58 188.10 .691 
        
Income   <$20,000†      
  $20,000-$39,999 81.68 31.29 20.36 143.01 .009* 
  $40,000-$59,999 154.22 42.15 71.61 236.84 .000* 
  ≥60,000 87.52 43.29 2.67 172.38 .043* 
        
Insurance Coverage  Private 175.71 32.08 112.84 238.57 .000* 
  Public 99.23 35.80 29.07 169.39 .006* 
  Uninsured†      
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Regression Model   B SE CI  Sig. (p) 
Variables  Levels   Lower  Upper  
Bound Bound 
Marital Status  Presently Married 76.45 26.05 25.40 127.50 .003* 
  Not Married†      
        
Region  Northeast 66.78 33.77 .60 132.96 .048* 
  Midwest 145.22 30.38 85.67 204.77 .000* 
  South†      
  West -30.00 28.46 -85.79 25.79 .292 
        
Multiple Linear Regression Analysis-Enter Method, all variables entered. *Significance is at 0.05 level. 
Dependent variable: Total Outpatient Expenditure 
†=Reference Category 
 B = Regression Coefficient; SE = Standard Error of the regression coefficients, CI= Confidence Interval, Sig= Significance level
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Regression results for total inpatient expenditures are shown in Table 11. 
Variables that were found significant in the regression model were age, income level, 
insurance coverage marital status and region in the US. Age groups that was significantly 
associated with higher expenditures were 49-58 years and ≥59 years ($891.18 and 
$2,353.81 respectively) compared to 39-48 years (reference category). Individuals with 
an income level of ≥$60,000 had $452.36 lower expenditures compared to individuals 
with <$20,000 income level (reference category). Individuals with private insurance as 
well as individuals with public insurance had higher inpatient expenditures ($554.47 and 
$1,111.31, respectively) compared to individuals who were uninsured (reference 
category). As seen in the results of earlier  regression models that were conducted for 
COPD, individuals with COPD who were presently married had higher inpatient 
expenditures ($214.81 higher) as compared to individuals with COPD who were not 
married (reference category). Compared to individuals in the southern region of the US, 
individuals in the Northeast region, Midwest region and Western region of the US had 
significantly lower inpatient expenditures ($327.20, $238.94 and $434.08 expenditures 
respectively). Although the regression results in Table 13 show that individuals with 
COPD incur higher inpatient expenditures than individuals without COPD, the result was 
not statistically significant.
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Table 11.  Predictors for total inpatient expenditures in 2007 for COPD 
Regression Model   B SE CI  Sig. (p) 
Variables  Levels   Lower  Upper  
Bound Bound 
        
Presence of condition  COPD 250.74 686.43 -1,094.69 1,596.17 .715 
  No COPD†      
        
Gender  Male 45.97 90.37 -131.16 223.11 .611 
  Female†      
        
Age in years  18-28 249.85 138.12 -20.87 520.58 .070 
  29-38 183.11 152.66 -116.11 482.32 .230 
  39-48†      
  49-58 891.18 154.18 588.99 1,193.37 .000* 
  ≥59 2,353.81 136.40 2,086.46 2,621.17 .000* 
        
Race  White -164.54 123.84 -407.27 78.19 .184 
  African American†      
  Native American -232.18 484.98 -1182.75 718.39 .632 
  Asian -164.74 241.71 -638.49 309.02 .496 
  Hawaaiian 826.92 766.28 -675.01 2,328.85 .281 
  Other -111.97 327.50 -753.88 529.94 .732 
        
Income   <$20,000†      
  $20,000-$39,999 -79.55 128.46 -331.35 172.24 .536 
  $40,000-$59,999 -291.65 173.07 -630.87 47.57 .092 
  ≥60,000 -452.36 177.76 -800.78 -103.95 .011 
        
Insurance Coverage  Private 554.47 131.70 296.34 812.60 .000* 
  Public 1,111.31 146.97 823.23 1,399.38 .000* 
  Uninsured†      
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*Multiple Linear Regression Analysis-Enter Method, all variables entered. *Significance is at 0.05 level. 
Dependent variable: Total Inpatient Expenditure 
†=Reference Category 
 B = Regression Coefficient; SE = Standard Error of the regression coefficients, CI= Confidence Interval, Sig= Significance level 
Regression Model   B SE CI  Sig. (p) 
Variables  Levels   Lower  Upper  
Bound Bound 
Marital Status  Presently Married 214.81 106.94 5.20 424.43 .045 
  Not Married†      
        
Region  Northeast -327.20 138.63 -598.93 -55.47 .018* 
  Midwest -238.94 124.74 -483.43 5.56 .055* 
  South†      
  West -434.08 116.87 -663.15 -205.02 .000* 
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In Table12, the regression results for emergency room expenditures for 
individuals with COPD are displayed. Variables that were significant in the regression 
model were age, race, income level, insurance coverage and region in the US. The age 
groups 18-28 years, 49-58 years and ≥59 years had higher emergency room expenditures 
($42.07, $88.56, and $78.03, respectively) compared to the age group 39-48 years (the 
reference category). Individuals who were Native American incurred $164.82 higher 
expenditures compared to individuals who were African-Americans (reference category). 
Also, individuals who reported having a mixed race incurred higher emergency room 
expenditures ($115.82 higher) compared to African-Americans. Among income level, 
individuals who had an income level of  ≥$60,000 per year, had $39.91 lower emergency 
room expenditures compared to individuals who had an income level of <$20,000 per 
year (reference category). It was also found that individuals who held a private insurance 
had $49.51 higher emergency room expenditures compared to individuals who were 
uninsured (reference category). Lastly, the Northeast region and Western region in the 
US were associated with lower emergency room expenditures ($37.74 and $34.95, 
respectively) compared to the southern region in the US (reference category).
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Table 12.  Predictors for total emergency room expenditures in 2007 for COPD 
Regression Model   B SE CI  Sig. (p) 
Variables  Levels   Lower  Upper  
Bound Bound 
        
Presence of condition  COPD -33.90 69.65 -170.41 102.62 .626 
  No COPD†      
        
Gender  Male -5.35 9.17 -23.33 12.62 .559 
  Female†      
        
Age in years  18-28 42.07 14.02 14.60 69.54 .003* 
  29-38 24.47 15.49 -5.90 54.83 .114 
  39-48†      
  49-58 88.56 15.64 57.90 119.22 .000* 
  ≥59 78.03 13.84 50.90 105.15 .000* 
        
Race  White .03 12.57 -24.60 24.66 .998 
  African American†      
  Native American 164.82 49.21 68.37 261.27 .001 
  Asian -33.80 24.53 -81.87 14.27 .168 
  Hawaaiian 59.64 77.75 -92.75 212.03 .443 
  Other 115.82 33.23 50.69 180.95 .000 
        
Income   <$20,000†      
  $20,000-$39,999 -3.43 13.04 -28.98 22.12 .793 
  $40,000-$59,999 -6.28 17.56 -40.70 28.14 .721 
  ≥60,000 -39.91 18.04 -75.26 -4.56 .027* 
        
Insurance Coverage  Private 49.51 13.36 23.32 75.70 .000* 
  Public 23.28 14.91 -5.95 52.51 .118 
  Uninsured†      
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Regression Model   B SE CI  Sig. (p) 
Variables  Levels   Lower  Upper  
Bound Bound 
 
 
 
 
 
 
 
Multiple Linear Regression Analysis-Enter Method, all variables entered. *Significance is at 0.05 level. 
Dependent variable: Total Emergency Room Expenditure 
†:Reference Category 
B = Regression Coefficient; SE = Standard Error of the regression coefficients, CI= Confidence Interval, Sig= Significance level
Marital Status  Presently Married 3.46 10.85 -17.81 24.73 .750 
  Not Married†      
        
Region  Northeast -37.74 14.07 -65.31 -10.17 .007* 
  Midwest 4.70 12.66 -20.11 29.51 .711 
  South†      
  West -34.95 11.86 -58.20 -11.71 .003* 
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Results for the multivariate regression analysis conducted for prescription 
expenditures in individuals with COPD are displayed in Table 13. Variables that were 
found significant in the regression model were gender, age, race, insurance coverage, 
marital status, and region in the US. It was found that males had $126.88 lower 
prescription expenditures compared to females. The age groups 29-38 years, 49-58 years 
and ≥59 years were associated with higher prescription expenditures ($129.80, $1,069.71, 
and $1,569.44, respectively) compared to the age group of 39-48 years (reference 
category in dummy variables). Asians had $151.63 lower prescription expenditures 
compared to African-Americans (reference category). Also, individuals who had reported 
mixed race incurred $225.80 higher prescription expenditures compared to African-
Americans. Individuals with private insurance or public insurance had higher prescription 
expenditures ($337.25, and $589.16, respectively) compared to individuals who were 
uninsured (reference category). Individuals who were presently married had $79.64 
higher prescription expenditures compares to individuals who were not married. Lastly, 
individuals in the Western region of the US had $182.66 lower expenditures compared to 
individuals in the southern region (reference category).
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Table 13.  Predictors for total prescription expenditures in 2007 for COPD 
 
Regression Model   B SE CI  Sig. (p) 
Variables  Levels   Lower  Upper  
Bound Bound 
        
Presence of condition  COPD 347.88 190.44 -25.38 721.15 .068 
  No COPD†      
        
Gender  Male -126.88 25.07 -176.02 -77.74 .000* 
  Female†      
        
Age in years  18-28 -14.96 38.32 -90.07 60.14 .696 
  29-38 129.80 42.35 46.78 212.81 .002* 
  39-48†      
  49-58 1,069.71 42.77 985.88 1,153.55 .000* 
  ≥59 1,569.44 37.84 1,495.27 1,643.61 .000* 
        
Race  White 120.97 34.36 53.63 188.31 .000* 
  African American†      
  Native American -2.29 134.55 -266.01 261.42 .986 
  Asian -151.63 67.06 -283.06 -20.19 .024 
  Hawaaiian 17.57 212.59 -399.11 434.25 .934 
  Other 225.80 90.86 47.72 403.88 .013 
        
Income   <$20,000†      
  $20,000-$39,999 -48.88 35.64 -118.73 20.98 .170 
  $40,000-$59,999 -55.35 48.01 -149.45 38.76 .249 
  ≥60,000 -19.62 49.32 -116.28 77.04 .691 
        
Insurance Coverage  Private 337.25 36.54 265.64 408.87 .000* 
  Public 589.16 40.78 509.23 669.08 .000* 
  Uninsured†      
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Regression Model   B SE CI  Sig. (p) 
Variables  Levels   Lower  Upper  
Bound Bound 
        
Marital Status  Presently Married 79.64 29.67 21.44 137.79 .007* 
  Not Married†      
        
Region  Northeast 18.25 38.46 -57.14 93.63 .635 
  Midwest 47.56 34.61 -20.27 115.39 .169 
  South†      
  West -182.66 32.42 -246.21 -119.12 .000* 
        
Multiple Linear Regression Analysis-Enter Method, all variables entered. *Significance is at 0.05 level. 
Dependent variable: Total Prescription Expenditure 
†=Reference Category 
 B = Regression Coefficient; SE = Standard Error of the regression coefficients, CI= Confidence Interval, Sig= Significance level
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Objective 5: Calculate national estimate for total incremental health care expenditure of 
treating COPD. 
To calculate the national estimate for the total incremental health care expenditures in 
COPD, the national prevalence of COPD was multiplied by the estimated incremental 
expenditure computed from the regression analysis. For COPD, the national estimate was 
calculated to be approximately $2.2 billion. 
National prevalence × Estimated Incremental Expenditure = National Estimate for Total 
Incremental Expenditure 
1,290,775 × $1739.27= $2,245,006,234.25 
 
Objective 6: Identify predictors for total health care expenditures in asthma in each 
service category 
A multivariate regression analysis was conducted for six expenditure categories similar to 
that described in Objective 5 to calculate the incremental health care expenditures 
associated with asthma. Table 14 displays results for regression analysis for total health 
care expenditures in the year 2007. Individuals with asthma had a $2,133.83 increment in 
terms of total health care expenditures. Variables found to be significant in the regression 
model were presence of asthma, gender, age, insurance coverage, marital status and 
region in the US. According to the regression results males have $409.22 lower 
expenditures than females. The age groups 49-58 years and ≥59 years had substantially 
higher expenditures compared to the age group 39-48 years. The age groups 49-58 years 
incurred $3,098.99 higher expenditures and the age group ≥59 years incurred $6,178.22 
 75 
  
 
higher expenditures. Furthermore, the results also indicated that individuals with public 
insurance incurred $2,385.65 higher expenditures and individuals with private insurance 
had $1,869.96 higher expenditures than the uninsured population. In addition to this 
individuals who were presently married had significantly higher expenditures ($457.79). 
Also, individuals in the Western region had significantly lower expenditures ($653.95) 
compared to individuals in the Southern region.
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Table 14. Predictors for total health care expenditure 2007 for asthma 
 
Regression Model   B SE CI  Sig. (p) 
Variables  Levels   Lower  Upper  
Bound Bound 
        
Presence of condition  Asthma 2,133.83 209.72 1,722.78 2,544.89 .000* 
  No Asthma†      
        
Gender  Male -409.22 123.82 -651.91 -166.91 .001* 
  Female†      
        
Age in years  18-28 191.83 189.17 -178.95 562.62 .311 
  29-38 379.72 209.08 -30.08 789.52 .069 
  39-48†      
  49-58 3,098.99 211.17 2,685.09 3,512.88 .000* 
  ≥59 6,178.22 186.80 5,812.08 6,544.35 .000* 
        
Race  White 218.18 169.66 -114.37 550.72 .198 
  African American†      
  Native American 116.84 664.23 -1,185.07 1,418.76 .860 
  Asian -504.00 331.16 -1,153.09 145.09 .128 
  Hawaaiian 838.05 1,049.41 -1,218.84 2,894.93 .425 
  Other 467.64 448.61 -411.65 1,346.93 .297 
        
Income   <$20,000†      
  $20,000-$39,999 -17.65 175.94 -362.51 327.21 .920 
  $40,000-$59,999 135.81 237.05 -328.82 600.43 .567 
  ≥60,000 -185.72 243.45 -662.89 291.44 .446 
        
Insurance Coverage  Private 1,869.96 180.53 1,516.12 2,223.80 .000* 
  Public 2,385.65 201.72 1,990.27 2,781.03 .000* 
  Uninsured†      
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Regression Model   B SE CI  Sig. (p) 
Variables  Levels   Lower  Upper  
Bound Bound 
        
Marital Status  Presently Married 457.79 146.51 170.62 744.96 .002* 
  Not Married†      
        
Region  Northeast -242.55 189.90 -614.75 129.65 .202 
  Midwest 135.75 170.85 -199.11 470.61 .427 
  South†      
  West -635.95 160.06 -949.67 -322.22 .000* 
        
Multiple Linear Regression Analysis-Enter Method, all variables entered. *Significance is at 0.05 level. 
Dependent variable: Total Health care Expenditure 
†=Reference Category 
 B = Regression Coefficient; SE = Standard Error of the regression coefficient, CI= Confidence Interval, Sig= Significance level
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Table 15 represents the regression results for total office-based expenditures 
associated with asthma in the year 2007. Significant variables in the regression model 
were presence of asthma, gender, age, income level, insurance coverage, marital status 
and region of the US. Individuals with asthma had significant incremental expenditures 
associated for office-based visits ($428.00). Males had $199.97 lower expenditures 
compared to females. The age groups 29-38 years, 49-58 years, and ≥59 years had 
substantially higher expenditures compared to the age group 39-48 years. Individuals 
with an income level of $40,000-$59,999, and ≥$60,000 had a significantly higher 
expenditure ($284.99 and $149.72, respectively). Individuals with private insurance had 
an incremental expenditure of $533.52 and individuals with public insurance had an 
incremental expenditure of $393.38 compared to the uninsured population.. Furthermore, 
individuals who were presently married incurred $183.09 higher expenditures compared 
to individuals who were not married. It was also found that individuals in the Midwest 
region of the US had $178.32 higher expenditures than individuals in the Southern 
region.
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Table 15.  Predictors for total office-based expenditure in 2007 for asthma 
 
Regression Model   B SE CI  Sig. (p) 
Variables  Levels   Lower  Upper  
Bound Bound 
        
Presence of condition  Asthma 428.00 64.72 301.15 554.85 .000* 
  No Asthma†      
        
Gender  Male -199.97 38.21 -274.87 -125.08 .000* 
  Female†      
        
Age in years  18-28 31.26 58.38 -83.16 145.68 .592 
  29-38 140.54 64.52 14.08 267.00 .029* 
  39-48†      
  49-58 600.66 65.17 472.94 728.39 .000* 
  ≥59 1,159.34 57.65 1,046.35 1,272.32 .000* 
        
Race  White 95.70 52.36 -6.921 198.32 .068 
  African American†      
  Native American 192.99 204.98 -208.77 594.76 .346 
  Asian -96.42 102.20 -296.73 103.89 .345 
  Hawaaiian -241.13 323.84 -875.88 393.61 .457 
  Other 86.74 138.44 -184.61 358.08 .531 
        
Income   <$20,000†      
  $20,000-$39,999 81.95 54.30 -24.47 188.37 .131 
  $40,000-$59,999 284.99 73.15 141.61 428.37 .000* 
  ≥60,000 149.72 75.13 2.47 296.97 .000* 
        
Insurance Coverage  Private 533.52 55.71 424.32 642.71 .000* 
  Public 393.38 62.25 271.37 515.40 .000* 
  Uninsured†      
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Regression Model   B SE CI  Sig. (p) 
Variables  Levels   Lower  Upper  
Bound Bound 
        
Marital Status  Presently Married 183.09 45.21 94.47 271.71 .000* 
  Not Married†      
        
Region  Northeast 80.90 58.60 -33.96 195.76 .167 
  Midwest 178.32 52.72 74.98 281.66 .001* 
  South†      
  West 32.04 49.39 -64.78 128.85 .517 
        
Multiple Linear Regression Analysis-Enter Method, all variables entered. *Significance is at 0.05 level. 
Dependent variable: Total Office Based Expenditure 
†=Reference Category 
B = Regression Coefficient; SE = Standard Error of the regression coefficient, CI= Confidence Interval, Sig= Significance level
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Regression results for expenditures in the outpatient service category associated with 
asthma are displayed in Table 16. Variables found to be significant were presence of 
asthma, age, income level, insurance coverage, marital status and region of US. Presence 
of asthma was associated with an incremental cost of $98.42 in the outpatient service 
category. The age group 49-58 years, and ≥59 years had significant incremental costs 
associated ($272.11 and $393.25, respectively). Individuals having an income level 
greater than $20,000 were also significantly associated with higher expenditures.  
Incremental expenditures associated with income levels $20,000-$39,999, $40,000-
$59,999, and greater than $60,000 were $82.09, $155.73 and $87.74, respectively. As 
seen in the previous service categories, expenditures associated with individuals who had 
private insurance ($172.32) and public insurance ($92.90) were higher compared to the 
uninsured population. The results show that the Northeast region ($65.38) and Midwest 
region ($144.74) had higher incremental expenditures. Furthermore, individuals who 
were presently married had $78.27 higher expenditures compared to individuals who 
were not married.
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Table 16. Predictors for total outpatient expenditures in 2007 for asthma 
 
Regression Model   B SE CI  Sig. (p) 
Variables  Levels   Lower  Upper  
Bound Bound 
        
Presence of condition  Asthma 98.42 37.29 25.33 171.51 .008* 
  No Asthma†      
        
Gender  Male -40.86 22.02 -84.01 2.29 .063 
  Female†      
        
Age in years  18-28 -45.27 33.64 -111.20 20.66 .178 
  29-38 -50.18 37.18 -123.05 22.69 .177 
  39-48†      
  49-58 272.11 37.55 198.51 345.70 .000* 
  ≥59 393.25 33.22 328.14 458.35 .000* 
        
Race  White 46.22 30.17 -12.91 105.35 .126 
  African American†      
  Native American 17.76 118.11 -213.74 249.26 .880 
  Asian -103.83 58.89 -219.25 11.59 .078 
  Hawaaiian 125.95 186.60 -239.80 491.69 .500 
  Other 28.30 79.77 -128.05 184.65 .723 
        
Income   <$20,000†      
  $20,000-$39,999 82.09 31.29 20.77 143.41 .009* 
  $40,000-$59,999 155.73 42.15 73.11 238.34 .000* 
  ≥60,000 87.74 43.29 2.90 172.59 .043* 
        
Insurance Coverage  Private 172.32 32.10 109.40 235.24 .000* 
  Public 92.90 35.87 22.59 163.20 .010* 
  Uninsured†      
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Regression Model   B SE CI  Sig. (p) 
Variables  Levels   Lower  Upper  
Bound Bound 
        
Marital Status  Presently Married 78.27 26.05 27.21 129.33 .003* 
  Not Married†      
        
Region  Northeast 65.38 33.77 -.80 131.57 .053* 
  Midwest 144.74 30.38 85.20 204.28 .000* 
  South†      
  West -29.70 28.46 -85.48 26.09 .297 
        
Multiple Linear Regression Analysis-Enter Method, all variables entered. *Significance is at 0.05 level. 
Dependent variable: Total Outpatient Expenditure 
†=Reference Category  
B = Regression Coefficient; SE = Standard Error of the regression coefficient, CI= Confidence Interval, Sig= Significance level
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Regression results for inpatient expenditures associated with asthma are displayed 
in Table 17. As observed in the previous service categories, incremental expenditures 
associated with asthma were higher in inpatient service categories as well. An 
incremental cost of $617.23 was associated with the presence of asthma. Other significant 
variables in the regression analysis included age, income level, insurance coverage, 
marital status and region in US. The age groups 49-58 years ($883.83) and ≥59 years 
($2.354.70) were associated with a higher incremental cost as observed in the results of 
previous service categories. Individuals with the income level of $60,000 and above had 
significantly lower costs ($448.84) compared to individuals who had an income of less 
than $20,000. Private insurance had an incremental cost of $532.29 and public insurance 
was associated with an incremental cost of $1,072.36 as compared to individuals who 
were uninsured. Also, individuals who were presently married incurred an incremental 
cost of $225.86 compared to individuals who were not married. Furthermore, compared 
to the Southern region in US, the Northeast ($336.01), Midwest ($242.21) and West 
($431.60) had significantly lower expenditures. 
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Table 17.  Predictors for total inpatient expenditures in 2007 for asthma 
 
Regression Model   B SE CI  Sig. (p) 
Variables  Levels   Lower  Upper  
Bound Bound 
        
Presence of condition  Asthma 617.23 153.09 317.18 917.28 .000* 
  No Asthma†      
        
Gender  Male 56.10 90.38 -121.05 233.25 .535 
  Female†      
        
Age in years  18-28 247.77 138.09 -22.89 518.43 .073 
  29-38 181.72 152.62 -117.42 480.85 .234 
  39-48†      
  49-58 883.83 154.14 581.70 1,185.96 .000* 
  ≥59 2,354.70 136.36 2,087.44 2,621.96 .000* 
        
Race  White -151.71 123.85 -394.46 91.04 .221 
  African American†      
  Native American -218.58 484.86 -1,168.92 731.77 .652 
  Asian -137.85 241.73 -611.66 335.96 .569 
  Hawaaiian 811.54 766.03 -689.90 2,312.98 .289 
  Other -135.61 327.47 -777.45 506.24 .679 
        
Income   <$20,000†      
  $20,000-$39,999 -76.73 128.43 -328.46 175.01 .550 
  $40,000-$59,999 -282.50 173.04 -621.66 56.66 .103 
  ≥60,000 -448.84 177.71 -797.16 -100.53 .012* 
        
Insurance Coverage  Private 532.29 131.78 274.00 790.58 .000* 
  Public 1,072.36 147.26 783.74 1,360.97 .000* 
  Uninsured†      
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Regression Model   B SE CI  Sig. (p) 
Variables  Levels   Lower  Upper  
Bound Bound 
        
Marital Status  Presently Married 225.86 106.95 16.24 435.49 .035* 
  Not Married†      
        
Region  Northeast -336.01 138.62 -607.70 -64.32 .015* 
  Midwest -242.21 124.71 -486.64 2.23 .052* 
  South†      
  West -431.60 116.84 -660.60 -202.60 .000* 
        
Multiple Linear Regression Analysis-Enter Method, all variables entered. *Significance is at 0.05 level. 
Dependent variable: Total Inpatient Expenditure 
†=Reference Category 
 B = Regression Coefficient; SE = Standard Error of the regression coefficients, CI= Confidence Interval, Sig= Significance level
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Regression results for Emergency room expenditures are displayed in Table 18. 
Presence of asthma was associated with an incremental cost of $73.31 compared to 
absence of asthma. Variables that were significantly associated with the expenditures in 
emergency room were age, race, income level, insurance coverage and region of US. The 
age groups 18-28 years ($41.84), 49-58 years ($87.74), and ≥59 years ($77.96) were 
associated with higher emergency room expenditures. Native Americans ($166.44) and 
other race category ($112.86) had higher expenditures compared to African Americans. 
Individuals with an income level of $60,000 and higher had $39.33 lower expenditures 
compared to individuals with an income level below $20,000. Also, individuals with 
private insurance ($46.80) had higher expenditures compared to the uninsured 
population. It was also noticed that the Northeast region ($38.79) and the Western region 
($34.61) of the US were associated with lower expenditures compared to the Southern 
region.  
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Table 18. Predictors for total emergency room expenditures in 2007 for asthma 
 
Regression Model   B SE CI  Sig. (p) 
Variables  Levels   Lower  Upper  
Bound Bound 
        
Presence of condition  Asthma 73.31 15.53 42.86 103.75 .000* 
  No Asthma†      
        
Gender  Male -4.20 9.17 -22.17 13.77 .647 
  Female†      
        
Age in years  18-28 41.84 14.01 14.39 69.30 .003* 
  29-38 24.22 15.48 -6.13 54.57 .118 
  39-48†      
  49-58 87.74 15.64 57.09 118.39 .000* 
  ≥59 77.96 13.83 50.85 105.08 .000* 
        
Race  White 1.55 12.57 -23.08 26.18 .902 
  African American†      
  Native American 166.43 49.19 70.02 262.85 .001* 
  Asian -30.66 24.53 -78.73 17.41 .211 
  Hawaaiian 56.88 77.72 -95.45 209.21 .464 
  Other 112.86 33.22 47.75 177.98 .001* 
        
Income   <$20,000†      
  $20,000-$39,999 -3.07 13.03 -28.61 22.47 .814 
  $40,000-$59,999 -5.21 17.56 -39.62 29.20 .767 
  ≥60,000 -39.33 18.03 -74.67 -3.99 .029* 
        
Insurance Coverage  Private 46.80 13.37 20.60 73.01 .000* 
  Public 18.72 14.94 -10.57 48.00 .210 
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Regression Model   B SE CI  Sig. (p) 
Variables  Levels   Lower  Upper  
Bound Bound 
        
Marital Status  Presently Married 4.75 10.85 -16.52 26.01 .662 
  Not Married†      
        
Region  Northeast -38.79 14.06 -66.35 -11.23 .006* 
  Midwest 4.29 12.65 -20.51 29.09 .735 
  South†      
  West -34.61 11.85 -57.85 -11.38 .004* 
        
Multiple Linear Regression Analysis-Enter Method, all variables entered. *Significance is at 0.05 level. 
Dependent variable: Total Emergency Room Expenditure 
†=Reference Category 
 B = Regression Coefficient; SE = Standard Error of the regression coefficients, CI= Confidence Interval, Sig= Significance level
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Regression results for prescription expenditures are displayed in Table 19. 
Variables found significant in the regression model were presence of asthma, gender, age, 
race, insurance coverage, marital status and region in the US. Presence of asthma was 
associated with an incremental cost of $760.72. Males had significantly lower 
expenditures associated with asthma as compared to females ($114.37 lower). Also, the 
age groups 29-38 years, 49-58 years and ≥59years were associated with a higher 
incremental cost as compared to the age group 39-48 years ($128.13, $1,060.62 and 
$1,570.63 higher respectively). In terms of race, the category for other races was 
associated with $196.77 higher expenditures compared to African-Americans. Also, the 
individuals with private insurance ($309.96) and public insurance ($541.11) had higher 
incremental expenditures compared to the uninsured population. This observation was 
consistent among expenditures in all six service categories. Furthermore, individuals who 
were presently married had $93.27 higher expenditures compared to individuals who 
were not married. Also, the Western region of the US was associated with significantly 
lower expenditures compared to the Southern region ($179.63 lower).
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Table 19.  Predictors for total prescription expenditures in 2007 for asthma 
 
Regression Model   B SE CI  Sig (p) 
Variables  Levels   Lower  Upper  
Bound Bound 
        
Presence of condition  Asthma 760.72 42.26 677.88 843.55 .000* 
  No Asthma†      
        
Gender  Male -114.37 24.95 -163.28 -65.47 .000* 
  Female†      
        
Age in years  18-28 -17.54 38.12 -92.27 57.18 .645 
  29-38 128.13 42.13 45.55 210.71 .002* 
  39-48†      
  49-58 1,060.62 42.56 977.21 1,144.03 .000* 
  ≥59 1,570.63 37.64 1,496.84 1,644.41 .000* 
        
Race  White 136.79 34.19 69.77 203.81 .000* 
  African American†      
  Native American 14.47 133.86 -247.90 276.84 .914 
  Asian -118.46 66.74 -249.26 12.35 .076 
  Hawaaiian -.816 211.48 -415.33 413.70 .997 
  Other 196.77 90.41 19.57 373.96 .030* 
        
Income   <$20,000†      
  $20,000-$39,999 -45.41 35.46 -114.90 24.09 .200 
  $40,000-$59,999 -44.06 47.77 -137.69 49.57 .356 
  ≥60,000 -15.39 49.06 -111.55 80.77 .754 
        
Insurance Coverage  Private 309.96 36.38 238.65 381.26 .000* 
  Public 541.11 40.65 461.44 620.79 .000* 
  Uninsured†      
   
 
     
    
 
9
2
 
Regression Model   B SE CI  Sig. (p) 
Variables  Levels   Lower  Upper  
Bound Bound 
        
Marital Status  Presently Married 93.27 29.53 35.40 151.14 .002* 
  Not Married†      
        
Region  Northeast 7.39 38.27 -67.61 82.40 .847 
  Midwest 43.54 34.43 -23.94 111.02 .206 
  South†      
  West -179.63 32.26 -242.85 116.41 .000* 
        
Multiple Linear Regression Analysis-Enter Method, all variables entered. *Significance is at 0.05 level. 
Dependent variable: Total Prescription Expenditure 
†=Reference Category 
 B = Regression Coefficient; SE = Standard Error of the regression coefficients, CI= Confidence Interval, Sig= Significance level
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Objective 7: Calculate national estimate for total incremental health care expenditure of 
treating asthma. 
To calculate the national estimate for the total incremental health care expenditures in 
asthma, the national prevalence of asthma was multiplied by the estimated incremental 
expenditure computed from the regression analysis. For asthma, the national estimate was 
calculated to be approximately $60 billion. 
National Prevalence × estimated incremental expenditure 
28,332,791 × $2133.83= $60,457,359,419.53 
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CHAPTER FIVE 
DISCUSSION AND CONCLUSIONS 
 
This chapter will present the discussion and draw conclusions based on the study 
results. Results for COPD will be discussed first followed by results for asthma. Study 
implications and limitations will also be discussed. 
 
The Household Component of MEPS 2007 data was utilized to estimate the 
prevalence and socio-demographic characteristics of individuals with COPD and asthma. 
The study also calculated the direct incremental expenditures associated with both the 
conditions and identified predictors of health care expenditures in COPD and asthma.  
 
  In 2007, the prevalence of COPD and asthma was approximately 1.3 million and 
28.3 million, respectively. The prevalence for COPD seemed to be an underestimation 
compared to the prevalence statistic of 16 million reported by COPD international in 
2004
5
 A possible reason for the underestimation could be that MEPS provides self-
reported data and survey respondents may have undiagnosed COPD that they may not be 
aware of. Another reason could be that MEPS provides data for US civilian non-
institutionalized population only and thus, individuals with COPD who reside in 
institutions (e.g., long term care facilities, nursing homes) were excluded from the MEPS 
sample.  Finally, a study conducted by Tinkelmann and colleagues have shown that 
COPD could be misdiagnosed as asthma resulting in underestimation of COPD cases. 
4
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The asthma prevalence reported by CDC in 2005 was 22.2 million.
11
  Our study reflects 
an increase in asthma prevalence to 28.3 million in 2007.  As mentioned earlier in the 
case of COPD, self reported data could increase chances of overestimating the prevalence 
of asthma. Also, COPD could be misdiagnosed as asthma thus overestimating the 
prevalence of asthma.  
 
 Although the COPD prevalence in our study could have been underestimated, the 
socio-demographic disparities identified among individuals with COPD are consistent 
with those reported by other studies. Our study found that COPD was more prevalent 
among males than females. According to the 2004 Surgeon General Report, males are 
more prone to the risk of developing COPD compared to women due to higher rates of 
smoking.
8  
 The report also states that COPD is a predominant condition among whites 
which is also supported by  published studies.
6,7,33,34 
 However, the MEPS study sample 
had a higher population of whites which could have in turn reflected a higher prevalence 
of COPD in whites. Our study shows that
 
COPD was more prevalent among individuals 
aged 59 years and older. Disease onset for COPD usually occurs in individuals who are in 
their mid 40s, thus, justifying the higher prevalence reported in this study for that 
particular age group.
50 
 Furthermore, our prevalence estimates for COPD according to 
different age groups was consistent with the study conducted by Miller & colleagues 
(2005) that used 2000 MEPS data.
27 
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COPD was found to be more prevalent in the Southern region and Midwestern 
region of the US. The Southern region and Midwestern region have higher smoking rates 
which is an important risk factor for  COPD.
51
  Also, individuals with an income level of 
less than $20,000 per year were more likely to have COPD according to our study results.  
Individuals with low socioeconomic status have been linked with higher exposure to 
occupational hazards such as dust and chemical fumes which are risk factors for 
developing COPD.
52
  Individuals who are exposed to these risk factors may have a higher 
chance of developing COPD. Smoking is a risk factor for developing COPD and since a 
lower socio-economic status is associated with higher rates of smoking, individuals in 
this group have a higher likelihood of developing COPD.
53
 
 
Similar to those reported for COPD, the disparities in socio-demographic 
characteristics for asthma were consistent with previous studies. Unlike COPD which is 
prevalent in males, asthma was found to be more prevalent in females consistent with 
other study results.
13,14
   It is not clearly understood why the prevalence is higher in 
females but there could be a possibility of differences in underlying physiological 
mechanisms that may explain a higher rate than males.
3  
Whites were more likely to have 
asthma compared to African Americans, Native Americans, Hispanics, Asians and other 
races. This finding is consistent with Kamble & colleagues (2009).
28
  Interestingly, other 
national findings report that asthma is more prevalent among African Americans.
13,14
  
This variation in prevalence estimates may be due to smaller sample size among African 
American individuals in the MEPS data. Our study reports a higher asthma prevalence 
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among individuals who were 59 years and older. A study conducted by Braman (2003) 
reports the highest prevalence of asthma among adults who are 65 years and older.
 54
   
 
Other findings that were consistent with national findings include higher 
prevalence of asthma among individuals who have an income level of less than $20,000 
per year, and among individuals in the Southern region of the US. Studies have shown 
that individuals with a lower socioeconomic status are more likely to be diagnosed with 
asthma.
55
  As discussed earlier, individuals with a low socio-economic status are more 
likely to be exposed to occupational hazards such as chemical fumes and dust. Exposure 
to these risk factors may explain the higher prevalence of asthma in individuals who have 
a low socio-economic status. CDC reports the Southern region of the US being correlated 
with a higher prevalence in asthma.
11 
 In the 2007 MEPS database, the sample size was 
higher for individuals in the Southern region, which could also be a reason for the higher 
prevalence of asthma reflected in this region.  
 
The second goal of the study was to estimate the total health care expenditure for 
COPD and asthma. The incremental estimate for total health care expenditure per person 
was $1,739.27 for individuals with COPD which translated into a national incremental 
total health care expenditures of $2.2 billion. As discussed earlier, since the prevalence of 
COPD in the current study seems to be underestimated, it is possible that the incremental 
expenditures calculated for these individuals could be underestimated as well compared 
to published estimates. Interestingly, the per person direct incremental total expenditure 
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in our study ($1,739.27) was slightly less than that reported by Miller & colleagues 
(2005) who used 2000 MEPS data ($2,507).
27
 A possible explanation for this could be 
due to the exclusion of home health care expenditures in this study. Also, Miller & 
colleagues used the multivariate linear least-squares regression instead of multiple linear 
regression, which could have affected the estimated incremental expenditures associated 
with COPD. 
 
The study further explored the contribution of different service categories to the 
total health care expenditures. Office-based expenditures ($610.55) contributed the 
highest to the total health care expenditures followed by Prescription expenditures 
($347.83). The NHLBI reports that COPD was responsible for 12.3 million physician 
office visits in 1999.
21
  With increasing prevalence of COPD over the years, office-based 
visits have become a major cost contributor to total health care expenditures associated 
with COPD.. Studies have also shown that prescription expenditures are a major cost 
contributor among individuals with COPD.
29,37
  Miller & colleagues (2005) also reported 
prescription expenditures as the major cost contributor to total health care expenditures 
using 1999 MEPS data.  Increased utilization and demand for prescription drugs could 
have contributed to the high prescription expenditures.
56 
 The number of prescriptions 
purchased in the US increased by  39% between the years 1999-2009. Furthermore, most 
of the top-selling prescriptions are higher priced brand name drugs e.g. Spiriva and 
Advair which could have contributed to the high prescription expenditures observed.
56
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Individuals with COPD who were 49 years old and above had higher health care 
expenditures compared to the other age groups. Higher prevalence of COPD in this age 
group explains the high health care expenditures incurred. Even though COPD was more 
predominant among males, our study found that females with COPD incurred higher 
health care expenditures compared to males.
 
 Studies have shown that females have better 
access to health care due to increased probability of insurance coverage through 
employment compared to men.
57,58
 Women also have increased access to public 
insurance as a result of Medicaid’s previous link with public assistance and child 
bearing.
58 
 Women are therefore, more likely to seek health care than men..
57,58 
  
 
 Our study reports higher health care expenditures among individuals with COPD 
who reside in the Southern region of the US. The Midwest region was also a strong 
predictor of health care expenditures among individuals with COPD.  A higher 
prevalence of COPD in the Southern region would contribute to higher resource 
utilization and higher health care expenditures to manage the disease.  Furthermore, a 
study conducted by Holt et.al (1997) reports higher health care resource utilization 
among individuals with COPD in the Southern region of the US.
60  
They further state that 
higher smoking rates in the Southern region and lower socioeconomic status among 
individuals may have influenced increased resource utilization.
60
  
 
The incremental health care expenditure associated with asthma was $2,133.83 
and the national estimate for total incremental health care expenditure was $60 billion. 
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Among different service categories, prescription expenditures ($760.72) were the highest 
among individuals with asthma followed by inpatient expenditures ($617.23). 
Prescription medications have been reported to be as the largest cost contributor towards 
total health care expenditures.
39,40,41 
 One of the commonly cited reasons is  better 
adherence to medication.
61
  Inpatient expenditures were the next largest cost contributor 
to total health care expenditures. Hospitalizations have been reported as a major cost 
contributor to total health care cost among individuals with asthma in previous studies 
due to inadequate use of controller medications and the costly prices of 
hospitalizations.
40,41
  According to our study results, expenditures due to inpatient 
hospitalizations were higher among the elderly population (45years and above). Elderly 
population is more prone to upper respiratory tract infections such as the common cold or 
flu which could exacerbate asthma symptoms thus leading to inpatient hospitalizations.  
Disease severity can also affect number of hospitalizations that occur in asthma.  
Majority of our study sample could have severe asthma which could lead to more 
inpatient hospitalizations thus increasing expenditures in this category. Emergency room 
expenditures contributed least to the total health care expenditures. Our study findings in 
terms of incremental costs in the six service categories (total health care, office based, 
inpatient, outpatient, emergency room, prescription expenditures), is consistent with cost 
estimates reported by Kamble & colleagues (2009) using 2004 MEPS data.   
 
It was noticed, that some of the important predictors for health care expenditures 
in individuals with asthma for all service categories were gender, age, insurance 
coverage, income level of an individual and region in the US. Males incurred less health 
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care expenditures in all six service categories. This could be due to the lower prevalence 
of asthma in males which would in turn result in lower resource utilization. Health care 
expenditures were higher among individuals who were of age 49 years and older and in 
the age group of 18-28 years. Higher prevalence in these age groups contributes to higher 
resource utilization and therefore higher health care expenditures. Studies report that 
most hospitalizations in asthma occur in individuals who are of age 49 years and above 
and between the ages 18-28 years which directly impact cost estimates.
56 
 
 Individuals with COPD and those with asthma who were uninsured incurred 
fewer health care expenditures compared to individuals who had public or private 
insurance. Individuals who are uninsured are less likely to seek health care due to limited 
access to health care services. As expected, access to health care among the uninsured 
population is limited which results in reduced health care service utilizations among these 
individuals. Studies have shown that there is a correlation between access to health care 
and insurance coverage and Individuals without health insurance are also less likely to 
seek medical care when required.
59
   
 
We found that individuals who had an annual income level of less than $20,000 
had higher incremental total expenditures, inpatient expenditures and prescription 
expenditures. It was also noticed that individuals with an annual income of $20,000 and 
above incurred higher office-based expenditures and outpatient expenditures. Asthma 
was more prevalent among individuals with an income of less than $20,000 per year 
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which explains the higher health care expenditure in this group.  These individuals most 
likely had coverage under Medicaid or Medicare which would make it possible for them 
to afford health care.  
 
The Southern region and the Midwestern region in the US were associated with 
higher health care expenditures. The expenditures were found to be consistently high 
among the six different cost categories (total health care, office based, inpatient, 
outpatient, emergency room, prescription expenditures). This is attributed to the higher 
prevalence of asthma in these regions of the US. Our cost estimates further correlate with 
the previously reported prevalence estimates and resource utilization estimates in the 
Southern region and Midwestern region of the US.
10 
 
STUDY IMPLICATIONS 
 
Results from our study are important to different stakeholders for several reasons. 
The estimates could serve as a guide for managed care organizations in selecting cost-
effective medications and in setting premiums for insurance plans. The cost estimates 
from this study could guide the government in making future decisions for allocation of 
resources and research funds for COPD or asthma. The incremental health care 
expenditures reported in this study could be included in other economic studies such as   
cost effectiveness studies of pharmaceuticals and health care interventions. Furthermore, 
this study presents distribution of expenditures among different service categories which 
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gives a better understanding of which service category contributes the most to total health 
care expenditure. Resource utilization can be minimized in the high cost categories by 
appropriate disease management programs. Providers can focus on identification of 
misdiagnosis of asthma, implementing proper screening techniques in at risk population, 
and patient education. . Although implementation of disease intervention programs may 
add additional costs, future resource utilization can be minimized in COPD and asthma 
which could promote cost savings. 
 
LIMITATIONS OF THE STUDY 
 
Our study has a few limitations that need to be considered when interpreting the 
results. First self reported data from a national survey was utilized. Individuals with 
COPD and asthma were identified based on the medical conditions they reported. This 
could potentially over-estimate or under-estimate disease prevalence. Also, self reported 
data can introduce recall bias depending on the time when the event occurred. 
 
Second, MEPS does not provide any data on disease severity and disease history. 
These could be important covariates in predicting total health care expenditures. Database 
studies have used prescription medications as a proxy. However, due to lack of 
information on the frequency of the prescription drug, the disease severity could not be 
accounted for. Our study estimates direct health care expenditures associated with COPD 
and asthma. Indirect costs due to lost productivity (missed work days), unpaid care, 
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premature death, pain and suffering was not taken into account in our analysis. In case of 
COPD, incremental expenditures could have been under-estimated because costs 
associated with long-term oxygen therapy were not included. Oxygen therapy has been 
reported as one of the most costly components of outpatient therapy.
32 
 Long-term oxygen 
therapy is usually provided in long-term care facilities. As mentioned earlier, MEPS does 
not provide data on individuals who reside in long-term care facilities which makes it 
difficult for us to compute costs associated with this therapy.  
 
It is also important to note that the prevalence reported for asthma in this study is 
reflective of the adult population and therefore may not be representative of the total 
burden of asthma in terms of prevalence and health care expenditures.  
 
FUTURE DIRECTIONS 
 
 Here are some ideas for future research that can be conducted in COPD and 
asthma. The prevalence of asthma is higher in African American women however there 
are no studies that explain the reasons behind this disparity. Future studies could explore 
the reasons behind this disparity.  Another study could explore the healthcare providers 
understanding of the two disorder given the increasing misdiagnosis of COPD and 
asthma. Future studies can also focus on computing the indirect costs associated with 
COPD and asthma. Also, it would be interesting to see how cost estimates could differ, 
using claims data. 
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CONCLUSION 
 
Our study calculated the prevalence of COPD and asthma for 2007. The 
prevalence was 1.3 million for COPD and 28.3 million for asthma. Socio-demographic 
characteristics associated with individuals suffering from either COPD or asthma were 
also explored. We found that both conditions were more prevalent among individuals 
who were of age 48 years and older. Both the conditions were also prevalent among the 
white population, individuals in the Southern region of the US and in individuals with an 
annual income level of less than $20,000. COPD was more prevalent among males while 
asthma was more prevalent among females. In the case of asthma, individuals between 
the ages 18-28 years also had a high prevalence.   
 
The total direct incremental health care expenditure for COPD and asthma was 
$2.2 billion and $60 billion, respectively. In the case of COPD, office-based expenditures 
were the largest cost contributor to total health care expenditures followed by prescription 
expenditures. For asthma, prescription expenditures were major contributors to total 
health care expenditures followed by inpatient expenditures. For both COPD and asthma, 
Emergency Room expenditures were not major cost contributors. The common predictors 
for health care expenditures in both conditions were gender, age, income level, insurance 
status and region of the US. 
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To summarize, our study demonstrates socio-demographic disparities in 
prevalence of COPD and asthma. Furthermore, our results clearly identify disparities in 
terms of expenditure and resource utilization for COPD and asthma according to different 
demographic variables. Our study further confirms the burden of COPD and asthma in 
terms of the health care expenditures incurred by individuals suffering from these 
conditions.  
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